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I. Introduction
From the dawn of human history, human beings have lived in
both natural and man-caused fear of "disease, famine, and war."
These menaces have engendered crucial turning points in human
history, on occasion seriously threatening the existence of
mankind. Despite the collaborative efforts of the international
community to tackle these menaces, they still remain serious
impediments to the sustainable welfare and peace of the global
community. However, the biotechnological revolution launched
in the second half of the last century has provided us with new
chances to cope with at least the natural calamities of disease and
famine more effectively. It is a palpable fact that, in the twentieth
century, newly advanced biotechnological innovations in the fields
of agricultural and pharmaceutical industries have radically
accelerated production of food and significantly improved
pharmaceuticals through revolutions of the agricultural and
medical industries.'
As we have already recognized since the late twentieth
century, modern biotechnology, born with the advent of genetic
engineering, has highly influenced human society. In particular, it
is envisioned that modern biotechnology will play a very
significant role in providing solutions to baffling problems
regarding food productivity, health, nutrition,2 medicine, energy,
protection of the environment,3 etc. Moreover, it is expected that,
in the near future, a myriad of newly produced genetically
modified organisms (GMOs) made possible by genetic
engineering will very likely be applied to agricultural products,
pharmaceuticals, medical treatment, environmental protection,
I See generally CHRISTOPHER ARUP, THE NEW WORLD TRADE ORGANIZATION
AGREEMENTS: GLOBALIZING LAW THROUGH SERVICES AND INTELLECTUAL PROPERTY
216-17 (2000); PHILIP W. GRUBB, PATENTS FOR CHEMICALS, PHARMACEUTICALS AND
BIOTECHNOLOGY: FUNDAMENTALS OF GLOBAL LAW, PRACTICE AND STRATEGY 249-51
(1999); FIONA MACMILLAN, WTO AND THE ENVIRONMENT 138 (2001); JAYASHREE
WATAL, INTELLECTUAL PROPERTY RIGHTS IN THE WTO AND DEVELOPING COUNTRIES 128
(2001); Yvonne Cripps, Patenting Resources: Biotechnology and the Concept of
Sustainable Development, 9 IND. J. GLOBAL LEGAL STUD. 119, 121-24 (2001); Sean D.
Murphy, Biotechnology and International Law, 42 HARV. INT'L L.J. 47, 51-56 (2001).
2 WATAL, supra note 1, at 128.
3 INTRODUCTION TO INTELLECTUAL PROPERTY: THEORY AND PRACTICE 587-88
(World Intellectual Prop. Org. ed., 1997).
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alternative fuel, and other purposes. In fact, these biotechnological
applications will likely help alleviate human hardships concerning
food, energy, health, and the environment, and may ultimately
promote human welfare worldwide.'
The future itinerary of biotechnological advance is, however,
not always rosy. Although it is true that modern biotechnology
may be a high-powered engine that can increase food productivity
and facilitate production of more effective medicines, it remains
questionable whether modern biotechnology can conclusively
contribute to solving the problems of global environmental
conservation, economic development of the developing world, and
inequity between parties taking the profits of biotechnological
innovation. Notwithstanding numerous promising products of
biotechnology, many people are still apprehensive about the
results of massive dispersion of genetically engineered products
into the environment. Will biotechnological applications actually
guarantee nothing but a mere promise to help the future of
humanity?
Indeed, biotechnology, as one of the oldest technologies in
human history, has been exploited in manufacturing wine and beer
involving processes using living organisms, as well as in the
selective breeding of plants and animals. However, its technical
importance has grown considerably in recent years.5 In
comparison to modem biotechnology, the above mentioned
classical methods of biotechnology and traditional selective
breeding of animals and plants, usually applied to produce dairy
products, bread, wine, or any desired genetic traits, have not been
distinctively problematic in terms of either national or
transnational regulations.6 However, various critical issues,
questions, and problems surrounding modern biotechnology7 have
4 Murphy, supra note 1, at 47.
5 INTRODUCTION TO INTELLECTUAL PROPERTY: THEORY AND PRACTICE, supra note
3, at 587.
6 Murphy, supra note 1, at 50.
7 Modem biotechnology was developed based on two basic techniques of
recombinant deoxyribonucleic acid (DNA) and hybridoma in the 1970s. In brief, the
recombinant DNA technology, as also referred to genetic engineering, is the technology
of inserting the foreign gene materials into cells, thereby making certain desired proteins.
The hybridoma technology is used to blend different types of immune cells, producing a
hybrid cell line creating monoclonal antibodies. GRUBB, supra note 1, at 225.
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kindled severe controversies with both domestic and international
dimensions.8
On the one hand, genetic engineering, midwife for the birth of
modern biotechnology, has made it possible to achieve more
benefits of biotechnological applications than classical breeding.
On the other hand, it has provoked keen controversies regarding
the technological aspect itself, its unknown results, and basic
policies controlling technological development. This paradoxical
feature mainly seems to come from its technological manipulation,
splicing gene materials from different varieties or species to cause
genetic recombination overthrowing the natural obstacle of sexual
incompatibility.9 More recently, scientists, applying genetic
engineering technology such as microinjection to higher life
forms, began to create transgenic plants or animals with improved
or transformed genetic characters for certain purposes.
Sometimes, this kind of technology has been applied even to
humans.'l As a result, newly developed transgenic animals, such
as pigs and other animals containing human genes, have been
created." In this respect, it has become possible for humans to
intervene in the process of alterations of biological materials or the
natural course of evolution, which has never before occurred in a
natural ecosystem.
More recently, cloning techniques, which were developed
from modem genetic engineering and have been used to clone
genes, plants, animals,' 2 or even human beings, have triggered
public contention. Stem cell research, nuclear transfer technology,
and their resulting "fabrication" of Dolly the sheep opened the
door to human cloning using an adult somatic cell. 3 The
application of this "Dolly method" to human cloning compels us
to rethink the conventional notions of regeneration of life and
8 See Murphy, supra note 1, at 50.
9 LI WESTERLUND, BIOTECH PATENTS: EQUIVALENCE AND EXCLUSIONS UNDER
EUROPEAN AND U.S. PATENT LAW 7, 16 (2002).
1o See generally GRUBB, supra note 1, at 225, 243-44, 249-51 (discussing, among
other things, the use of gene therapy to address genetic defects).
II Donna M. Gitter, Led Astray By the Moral Compass: Incorporating Morality
Into European Union Biotechnology Patent Law, 19 BERKLEY J. INT'L L. 1, 6 (2001).
12 WESTERLUND, supra note 9, at 8.
13 In vitro fertilization works using a technique of embryo splitting has been
employed for human cloning since the early 1990s.
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human dignity, as well as many unresolved scientific and technical
problems. 14 Although there is great promise for medical
breakthroughs, we can anticipate that this application of modem
biotechnology will soon raise daunting challenges to existing legal
definitions of life, humanity, and personality.15
As mentioned above, according to the rapid pace of high-
biotechnology developments, both technical and legal problems
specific to biotechnology have arisen. In particular, the legal
issues surrounding modem biotechnological innovations have
centered mostly on strengthening protection of intellectual
property rights. This new tide of issues also requires us to take a
new look at the concept of traditional patent law systems in this
field. 6 Globally speaking, on the other hand, a more fundamental
question whether modem biotechnology can help maintain or
promote sustainable development of human beings, as well as
agriculture, has been raised. This proposition also tends to take a
composite phase in that legal consideration of biotechnology
commonly demands triangular analysis within the interrelated
framework of international intellectual property laws, international
trade laws, and international environmental laws.
The protection of biotechnological products is of immense
significance in commercial and industrial contexts. 7 Arguably,
genetically modified products should also be protected as
intellectual property resulting from human creativity. But the
intellectual property protection of biotechnology, which has
undoubtedly been a pivotal incentive stimulating research,
innovations, investments, inventions, and release of such
inventions, 8  has lagged behind the current industrial
developments in the field of biotechnology. 9 Even though patents
14 See Cripps, supra note 1, at 124-25.
is Id. at 123-24.
16 PHILLIPE G. DUCOR, PATENTING THE RECOMBINANT PRODUCTS OF
BIOTECHNOLOGY AND OTHER MOLECULES 1 (1998).
17 GRUBB, supra note 1, at 225.
18 See generally ARUP, supra note 1, at 219; WESTERLUND, supra note 9, at 9-11;
Thomas Cottier, The Protection of Genetic Resources and Traditional Knowledge:
Towards More Specific Rights and Obligations in World Trade Law, 1 J. INT'L ECON. L.
555, 569 (1998).
19 In addition, the intellectual property rights within the biotechnological field can
be a negotiating tool between the investors and researchers, and an organizing tool of
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on gene sequences, higher levels of life,2" or gene-technological
products have been bitterly controversial, useful products could be
commercially produced from genetically engineered transgenic
plants or animals.21
As we have seen, there have been extreme pros and cons
regarding new biotechnological development and its full
exploitation. This discord mainly stems from the unforeseeability
of the development and the unrevealed risks in biotechnological
areas that will evolve in the future.22 While it is rather paradoxical
that development of modem biotechnology may have both
promises and perils, these contradictory arguments are being made
worldwide. In the end, there is a strong probability that
transnational concerns over biotechnological applications, such as
whether and on what grounds countries may regulate international
trade of GMOs, whether genetic engineering will give rise to
environmental harm through "genetic pollution," and whether
GMOs have adverse effects on worldwide biological diversity,
will be a tremendous challenge to the global society.23
The controversial issues surrounding modem biotechnology
include consumer and environmentalist concerns regarding
GMOs, ranging from public health and environmental protection
quality and quantity controls. Moreover, it is pointed out that recent intellectual property
needs to be appreciated not only in terms of international, cultural, social, and
environmental dimensions, but also within the context of global trade and investment
flows. ARUP, supra note 1, at 219-20.
20 Unlike that of the higher life-forms, the patenting issue of microbiological
inventions, which encompass microbiological processes and the products of such
processes (e.g. micro-organisms), is comparatively less problematic. The term micro-
organism has broad meaning to include animal and plant cells as well as bacteria, fungi,
and viruses. At both the national and international levels, these microbiological
processes and micro-organisms are usually patentable and protected more strongly than
plant and animal varieties if they meet the general requirements for patents. GRUBB,
supra note 1, at 226-28.
21 WESTERLUND, supra note 9, at 7-9, 16.
22 "Technology, strictly speaking, involves human control. Thus, processes which
may be entirely controlled by man in a specific way, or products which are made by man
according to scientific principles involve the use of technology. The field of biology,
however, was traditionally considered to be beyond the scope of technology as it could
not be controlled in a predictable way by man." INTRODUCTION TO INTELLECTUAL
PROPERTY: THEORY AND PRACTICE, supra note 3, at 587.
23 Murphy, supra note 1, at 47-48.
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to ethical issues.24 Consumers and environmental groups, in fear
of currently hidden but arguably intrinsic risks to both humans and
the environment, insist that broad introduction of GMOs into the
environment without proof of environmental harmlessness be
restricted. 25 Environmentalists also argue that it should not be
overlooked that diffusion of GMOs can also threaten biological
diversity because of its unanticipated environmentally unfriendly
effects.26  With regard to medical applications of modem
biotechnology, particularly cloning and transgenic techniques,
more profound questions of the moral and ethical issues like
identity or dignity of life have proved to be similarly
controversial.27
The international community has scrutinized, in terms of
morality (or ordre public), ethics, and human dignity, both the
commercialized uses of biotechnology, such as commodification
of genetic resources, genetic information, human genes, human
beings, and higher life forms, and the application for patents for
these uses. Accordingly, the scope and ground for granting or
denying the intellectual property protection of genetic materials
have been divergent among different groups, organizations,
research institutions, industrial entities, regions, jurisdictions, and
countries. 28  To date, ethical, legal, and social implications of
24 MACMILLAN, supra note 1, at 139.
25 Murphy, supra note 1, at 57.
26 See Cripps, supra note 1, at 126.
27 See id. at 123-26.
28 For more details concerning this discussion, see generally ARUP, supra note 1, at
230-33; DERYCK BEYLEVELD & ROGER BROWNSWORD, HUMAN DIGNITY IN BIOETHICS
AND BIOLAW 196-205 (2001); GRUBB, supra note 1, at 252-60; Rebecca S. Eisenberg,
Genomic Patents and Product Development Incentives, in HUMAN DNA: LAW AND
POLICY 373, 373-78 (Bartha Maria Knoppers et al. eds., 1996); Jean-Christophe Galloux,
The Patentability of the Human Genome: A European Perspective, in HUMAN DNA:
LAW AND POLICY 361, 361-71 (Bartha Maria Knoppers et al. eds., 1996); Ruth Macklin,
The Ethics of Gene Patenting, in GENETIC INFORMATION: ACQUISITION, ACCESS, AND
CONTROL 129, 129-37 (Alison K. Thompson & Ruth F. Chadwick eds., 1999); Marilia
Bernardes Marques, Ethical Impacts of Human Health-Related Biotechnology in Brazil,
in GENETIC INFORMATION: ACQUISITION, ACCESS, AND CONTROL 163, 163-74 (Alison K.
Thompson & Ruth F. Chadwick eds., 1999); Randall W. Marusyk & Ariadni
Athanassiadis, Patenting of Human Genetic Sequences in Canada, in HUMAN DNA:
LAW AND POLICY 343, 343-60 (Bartha Maria Knoppers et al. eds., 1996); Godfrey B.
Tangwa, Genetic Information : Questions and Worries from an African Background, in
GENETIC INFORMATION: ACQUISITION, ACCESS, AND CONTROL 275, 275-81 (Alison K.
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patent application to genetic resources and commercialization of
genetic materials have been universally studied. In the near future,
however, neither a legally nor an ethically general consensus
concerning the problems of commercial exploitations of genetic
materials will probably be achieved. In addition, the legal status
of genetic resources as a commodity is likely to remain uncertain.
After the advent of Dolly the sheep, in particular, the issues of
legitimacy and the admissible scope of protection of human DNA
cloning technology and its results have been one of the hottest
potatoes in international intellectual property regimes, as well as in
the scientific world.29
We may find ourselves in the turmoil of the new
biotechnological millennium. In this biotechnological age,
technical and legal handling of modem biotechnology and its
resulting products, such as GMOs, is one of the major "socio-
scientific" issues." As of now, the global community has
established no international legal regime comprehensively dealing
with all of these "socio-scientific" issues. Instead, fragmentary
treaties or conventions regulate the relevant issues, respectively.
Therefore, global society urgently demands a formation of
standardized multilateral norms. These norms beyond the existing
legal regime should cover intellectual property protection, trade,
and environmental concerns to grapple more effectively with
emerging questions in the field of biotechnology."
Of these "socio-scientific" issues relating to biotechnology,
Thompson & Ruth F. Chadwick eds., 1999).
29 DoRis ESTELLE LONG & ANTHONY D'AMATO, A COURSEBOOK IN
INTERNATIONAL INTELLECTUAL PROPERTY 178-79 (2000).
30 MACMILLAN, supra note 1, at 138.
31 Steve Charnovitz addresses the policy linkage like the so-called "trade and" as
an old phenomenon or a long tradition since the beginning of international trade regimes,
including the General Agreement on Tariffs and Trade (GATT). In fact, according to his
explanation, international trading systems have incorporated non-trade concerns as well
as the trade liberalization purpose, and the linking issues are inherently appropriate.
Particularly, the link between trade and intellectual property and the link between trade
and environment can arguably be good examples of profitable linkage. He further insists
that the WTO itself may be the greatest institutional model of policy linkage, including
lots of trade-related issues such as intellectual property rights. Four main reasons set
forth for this linkage are i) policy effectiveness, ii) balancing spillovers, iii) political
coalitions, and iv) economies of scale. STEVE CHARNOVTZ, TRADE LAW AND GLOBAL
GOVERNANCE 11-25 (2002).
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environmental issues mostly concern protection of biodiversity
within the context of sustainable development. As modem
biotechnology has developed strikingly in these days, it is
necessary to take into more careful account adverse environmental
impacts made possible by biotechnological applications. As the
Agreement on Trade-Related Aspects of Intellectual Property
Rights (TRIPs Agreement), which is one of the annexed
multilateral agreements to the World Trade Organization (WTO),32
makes obvious, the ethical issues of biotechnology have, in part,
included environmental concerns, 33 such as sustainable use of
resources and sustainable development.
Sustainable development has become one of the major themes
in many international conventions and conferences concerning
environmental protection. 34 Recently, the World Court referred to
it as a principle of international environmental law, recognizing
the need for balancing between environmental protection and
development.35  Sustainable development, however, should be re-
examined in this biotechnological era because the miraculous
advance of modern biotechnology may eventually turn out to have
a seriously adverse influence on the environment. Protection of
biological diversity is another environmental issue surrounding
32 As a result of the Uruguay Round (UR) negotiations, the TRIPs Agreement, an
integral part of the WTO, was concluded. Compliance with the TRIPs Agreement is a
condition of membership of the WTO and it automatically binds all WTO members.
ARUP, supra note 1, at 178; BERNARD M. HOEKMAN & MICHEL M. KosTECKI, THE
POLITICAL ECONOMY OF THE WORLD TRADING SYSTEM: THE WTO AND BEYOND 285-90
(2d ed. 2001); see MACMILLAN, supra note 1, at 27-28.
33 The TRIPs Agreement says "Members may exclude from patentability
inventions, the prevention within their territory of the commercial exploitation of which
is necessary to protect ordre public or morality, including to protect human, animal or
plant life or health or to avoid serious prejudice to the environment .... " Agreement of
Trade-Related Aspects of Intellectual Property Rights, Annex IC of the Marrakesh
Agreement Establishing the World Trade Organization, Apr. 15, 1994 art. 27.2,
available at http://www.wto.org/english/tratop-e/trips-e/tagm0-e.htm.
34 James M. Sheehan, Sustainable Development: The Green Road to Serfdom?, in
THE GREENING OF U.S. FOREIGN POLICY 143, 143-44, 146-52 (Terry L. Anderson &
Henry I. Miller eds., 2000).
35 See, e.g., Gabcikovo-Nagymaros Project (Hung. v. Slovk.), 1997 I.C.J. 92 (Sept.
25). In particular, the separate opinion of Vice-President Weeramantry concerning the
concept of sustainable development is noteworthy. See DAVID HUNTER ET AL.,
INTERNATIONAL ENVIRONMENTAL LAW AND POLICY 336-46 (2d ed. 2002).
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biotechnology. 6  Biotechnology and GMOs may be a double-
edged sword involving both promises for sustainable use of
resources through environmentally sound technologies and perils
to biodiversity through unexpected harmful interactions with the
environment.37
Biotechnology, therefore, on the one hand will be helpful to
biodiversity by slowing down the decline of biological diversity,
but on the other hand, it can speed up the deterioration of
biodiversity. Somewhat ironically, decreases of biological
diversity may be more likely to happen when GMOs enjoy strong
international intellectual property protection.3 8 Consequently,
international intellectual property protection systems may have a
paradoxical feature in the context of sustainable development. For
example, an international depositary system of patented genetic
materials cannot be desirable for biodiversity because access to
deposited genetic materials will be suspended for the time being. 9
On the contrary, this regime provides a means to preserve those
materials for future generations.4" Thus, biodiversity-friendly
technology based on sustainable use of gene varieties in
sustainable methods may be a significant thrust for food security
and human survival.4'
Sustainable development, which emerged as an international
environmental discipline in the 1980s, and its more recent version,
"environmentally sustainable development," are products of an
enthusiastic experiment to reconcile the interests between
development and environmental protection and between
developing and developed countries which are conflicting at first
36 Cripps, supra note 1, at 126. Sustainability includes a biodiversity aspect. A
principal question is how many different or various breeds are used in the agroecosystem
overall. Ellen Messer, Food Systems and Dietary Perspective: Are Genetically Modified
Organisms the Best Way to Ensure Nutritionally Adequate Food?, 9 IND. J. GLOBAL
LEGAL STUD. 65, 85-86 (2001).
37 Cripps, supra note 1, at 119, 121-23, 126-27.
38 Murphy, supra note 1, at 95-96.
39 See id. at 96.
40 Cripps, supra note 1, at 122-23. On the one hand, plant genetic resources,
application of recombinant DNA technology to agricultural research, and bioprospecting
may be important sources for future biodiversity. On the other hand, dissemination of
bioprospecting may spur the loss of biodiversity. MACMILLAN, supra note 1, at 118-19.
41 See Cottier, supra note 18, at 558.
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glance.42 The problem of harmonizing them is still disputable.43
In this respect, it has also been questionable whether globalization
of patent systems and commercial interests concerning
biotechnology will be able to contribute to the protection of
genetic diversity and equitable use of and sustainable access to
genetic materials without prejudice to biodiversity.44
Accordingly, it should be equally noted that sustainable
development issues surrounding intellectual property protection of
biotechnological inventions concern issues of equity.45 Broadly
speaking, these equity concerns can be divided into two related but
distinct categories: equity between developing and developed
countries, and equity between present and future generations.46
The former means fair and equitable sharing of benefits between
developing countries with rich genetic resources and developed
countries exploiting and patenting the genetic materials from
developing countries. 47 The latter represents even-handedness in
splitting the profits from genetic resources in such a manner as
will promote sustainability.48
The topic of intellectual property protection of modern
42 A. Dan Tarlock, Ideas Without Institutions: The Paradox of Sustainable
Development, 9 IND. J. GLOBAL LEGAL STUD. 35, 35-40 (2001).
43 Id.
44 Ikechi Mgbeoji, Patents and Traditional Knowledge of the Uses of Plants: Is a
Communal Patent Regime Part of the Solution to the Scourge of Bio Piracy?, 9 IND. J.
GLOBAL LEGAL STUD. 163, 163-64 (2001).
45 Concerns about equity have been the heart of the issues of international
environmental law and sustainable development. Edith Brown Weiss, Environmental
Equity: The Imperative for the Twenty-First Century, in SUSTAINABLE DEVELOPMENT
AND INTERNATIONAL LAW 17, 17-18 (Winfried Lang ed., 1994).
46 "[F]uture generations are a silent but important party to debates about equity,"
and "[s]ustainable development is inherently intergenerational." Id. at 21. Further,
biotechnology can also have the meaning of equity between consumers, between users
and patentees, and between trade and the environment.
47 WATAL, supra note 1, at 129.
48 Cottier, supra note 18, at 564. In the context of sustainable development, the
consideration of future generations has been discussed in the theoretical, economic, and
legal perspectives, and insisted to be a "new global ethic." And also the welfare or
benefit of future generations and the notion of protecting nature for the future
generations have been suggested within the international environmental law aspect.
Finally, the concept of "the rights of future generations," as a ground for protecting the
environment, was presented. ALEXANDER GILLESPIE, INTERNATIONAL ENVIRONMENTAL
LAW, POLICY AND ETHICS 107-10 (1997).
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biotechnology, in the context of sustainable development, is so
broad that it spans areas of trade, environment, biodiversity,
equity, ethics, and humanity, as well as patent systems. To
conclude, intellectual property rights of biotechnology should not
be harmful, but only beneficial to all of these sides. Accordingly,
from the perspective of a multilateral legal approach, intellectual
property protection of biotechnology should be the most
appropriate instrument for promoting environmental protection,
biodiversity, and, ultimately, sustainable development.
Biotechnology, which may be one of the key technical codes to
sustainable development in the twenty-first century, represents a
"socio-scientific" dilemma in the existing global legal system. In
the context of sustainable development, future international legal
regimes for biotechnology, therefore, should equivalently embrace
essentials of "diversity" and "equity."
Among the global issues surrounding intellectual property
protection of biotechnology, its arguably adverse impacts on the
environment and sustainable development are the most
controversial. In brief, whether it can promote or destroy
biological diversity is still pending. With due regard to this
situation, this paper attempts to take an overview of the notion of
sustainable development in the context of modem
biotechnological developments. The paper also suggests an
evolutionary approach to the harmonization of intellectual
property protection of biotechnology and sustainable development.
To do this, the paper analyzes the implications of existing rules,
reappraises the current definition of sustainable development, and
reviews the applicability of evolving principles in relation to
modem biotechnology, with special reference to biodiversity and
equity between parties.
Chapter II begins with technical, legal, social, and ethical
contemplations on modem biotechnology in this new
biotechnological era. In addition, the paper reviews the debates
concerning applications of biotechnology and the general
definition and status of sustainable development in international
legal instruments.
Chapter III discusses the appropriateness of current definitions
and the scope of sustainable development in light of recently
advanced biotechnology. In particular, the paper considers the
redefinition and extension of the meaning of sustainable
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development with regard to very rapid and varied developments in
the field of biotechnology. The paper then reviews the existing
international legal provisions that may be applied to biotechnology
and sustainable development concerns. This discussion focuses on
the relevant provisions in the WTO structure with concomitant
reference to multilateral environmental treaties and major
transnational patent law systems.
Chapter IV addresses the appropriate intellectual property
protection of biotechnology for promoting sustainable
development, particularly by a polysynthetic approach to
biodiversity and equity. This chapter also analyzes globally
developing rules which may be contributory to the achievement of
harmonization and balance between intellectual property
protection of biotechnology and sustainable development.
This study mainly concludes that sustainable development, as
Professor Cripps suggests,49 should be redefined or modified with
regard to current biotechnological development. At the same time,
the scope and extent of intellectual property protection of
biotechnology should be decided in conformity with the principle
of sustainable development. Accordingly, this work seeks to
explore the relationship between patenting biotechnological
inventions and sustainable development, based on a three-
dimensional approach: intellectual property protection,
biodiversity, and equity. At this point, it should also be noted that
one has to take into full consideration all the relevant factors when
determining the appropriate scope of the protection.
In conclusion, not only sustainable developments of
agriculture and humans, but also economically sustainable
development and environmentally sustainable development may
be converged by adopting an evolutionary interpretation of
'biotechnologically sustainable development.' In addition,
sustainable development, as an evident conservation-relevant
factor, should be taken into ample account in interpreting and
applying the relevant provisions, such as patentable subject matter
49 Professor Cripps argues that the concept of sustainable development has been
somewhat mistakenly confined to sustainable agriculture in spite of the consensus about
its context. For her, the definition and perceptions of sustainable development should be
reconsidered according to the recent development of genetic engineering and human
cloning techniques to include sustainable development of humans outside the agricultural
context. See generally Cripps, supra note 1, at 121-26, 133.
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in the TRIPs Agreement, as well as other international
instruments, to regulate and avoid abuse or misuse of modem
biotechnology.
II. Implications of Modern Biotechnology on Sustainable
Development in the New Biotechnological Millennium
A. Changes in Technological and Legal Environments
The modem biotechnological revolution is one of the most
important technological advances in the late twentieth century.5"
Indeed, biotechnology, as one of the oldest technologies in human
history,51 has been commonly used to produce useful products
from living micro-organisms and traditionally adopted to
systematic cross-breeding of sexually compatible plants within the
same varieties or species for a long time.52 Since the second half
of the last century, however, this kind of technology has extended
to the innovation of so-called "genetic engineering," whereby it
becomes possible to remove a specific gene of one variety or
species and insert it into other varieties or species.53
Due to the scientific development of these biotechnological
processes, scientists can artificially manipulate living organisms or
modify genes. 4 Through the processes of genetic manipulation,
which came to be entirely controlled by man, we are able to
change the hereditary characteristics of living organisms to create
GMOs containing certain desirable genetic features.55 As a result,
there is a stronger possibility that modem biotechnology will play
a very important role in our future, particularly in the fields of
medicine, food, energy, protection of the environment, and so on.56
Scientists, applying genetic engineering techniques such as
microinjection (used to introduce foreign genes into the cells of
50 DUCOR, supra note 16, at 1.
51 INTRODUCTION TO INTELLECTUAL PROPERTY: THEORY AND PRACTICE, supra note
3, at 587.
52 GRUBB, supra note 1, at 224-25.
53 ARUP, supra note 1, at 215-16.
54 INTRODUCTION TO INTELLECTUAL PROPERTY: THEORY AND PRACTICE, supra note
3, at 587-88.
55 Id. at 588.
56 Id. at 587-88.
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higher life forms), have created transgenic plants and animals with
improved or transformed genetic characters for certain purposes.57
More recently, those techniques have been applied to medical
treatment of human diseases, namely gene therapy methods.5 8
The advent of modem biotechnology, born with genetic
engineering techniques, means that it becomes possible that
biological materials can be artificially changed or the natural
course of evolution can be more radically altered under human
control, which has never been able to occur in natural ecosystems.
Consequently, newly developed transgenic animals, such as pigs
and other animals including human genes, have been created.5 9 It
is anticipated, however, that these results of biotechnological
applications will cause a serious challenge to the existing legal
definitions of life, humanity, and personality in the near future.6"
Moreover, cloning techniques, which have been used to clone
genes, plants, animals,6 and more recently applied even to clone
human beings, have triggered severe public contention. Stem cell
research and nuclear transfer techniques, through which Dolly the
sheep was created, are likely to open the door to cloning a human
being from an adult somatic cell.62
In fact, the modem biotechnology of genetic engineering,
particularly that developed during the last two decades, has
extensively influenced human life. It cannot be denied that the
newly improved techniques have made the most remarkable
contributions to both food production, through agricultural
innovation, and the medical field, through the industrial advance
of pharmaceuticals.63 It is surely true that intellectual property
protection of biotechnological inventions has been an essential
element in the current development in the field of biotechnology
57 GRUBB, supra note 1, at 225, 243-44, 249-5 1.
58 Id.
59 Cripps, supra note 1, at 123.
60 Id. at 123-24.
61 WESTERLUND, supra note 9, at 8.
62 In vitro fertilization work using a technique of embryo splitting has been
employed for human cloning since the early 1990s. See generally Cripps, supra note 1,
at 124-25.
63 See generally MACMILLAN, supra note 1, at 138; Murphy, supra note 1, at 51-56;
WATAL, supra note 1, at 128; see also ARuP, supra note 1, at 216-17; Cripps, supra note
1, at 121-24; GRUBB, supra note 1, at 249-51.
[Vol. 29
IP PROTECTION OF BIOTECHNOLOGY
industries.64  However, since useful products could be
commercially produced from genetically engineered transgenic
plants or animals, patents on gene sequences, higher levels of life,
and gene-technological products have been the center of
controversies.65
As biotechnology has developed enormously in the late
twentieth century, the legal systems concerning intellectual
property protection of modern biotechnology, particularly patent
law focusing on patentability of biotechnological inventions, have
extensively changed in both the national and international spheres.
These changes in legal aspects have, of course, stemmed from the
complexity of biotechnological processes and inventions.66
Indeed, the importance of biotechnology has grown considerably
in recent years.67  Because of the rapid pace of modern
biotechnological development, which is one of the most important
technological breakthroughs in the last century, not only technical
but also legal problems specific to biotechnology have been
created.68 The legal issues surrounding modern biotechnological
innovations have mostly centered on reinforcement of protection
of intellectual property rights.69  These changes in the
technological and legal aspects of biotechnology have also
required taking a new look at the concept of traditional patent law
systems in this field.7"
Unlike classical methods of biotechnology or traditional
selective breeding of animals or plants, which have not been
especially problematic for either national or transnational
regulations,7 modern biotechnology, which was developed based
on the two basic techniques of recombinant DNA and hybridoma
in the 1970s, has fueled various critical issues, questions, and
64 See generally ARUP, supra note 1, at 219; WESTERLUND, supra note 9, at 9-11;
see also Cottier, supra note 18, at 569.
65 WESTERLUND, supra note 9, at 7-9, 16.
66 Id. at 1-21.
67 INTRODUCTION TO INTELLECTUAL PROPERTY: THEORY AND PRACTICE, supra note
3, at 587.
68 DUCOR, supra note 16, at 1.
69 Id.
70 Id. at 1-4.
71 Murphy, supra note 1, at 50.
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problems with transnational as well as national dimensions.72 In
particular, genetic engineering, the midwife for the birth of
modem biotechnology, provokes keen controversies about the
technique itself, its unknown results, and the basic policies
controlling the technological development, despite its more
effective benefits than ever.73 As already pointed out, this
paradoxical character of modem biotechnology mainly seems to
result from the capacity of genetically recombining genetic
materials between different varieties or species despite the fact
that they are sexually incompatible.74
Socially speaking, it should be noted that benefits derived from
modem biotechnological developments, in many cases, will
largely make a very limited number of enterprises in the developed
world richer rather than improve the general welfare of mankind."
This is the reason that biotechnological issues in modem society
should be analyzed based on both aspects of "diversity" and
"equity." As of now, the global community has established no
international legal regime comprehensively dealing with all of
these "socio-scientific" issues.76 Instead, fragmentary treaties or
conventions regulate the relevant issues individually.
This era can be characterized as "the biotechnological
millennium" of scientific, technological, industrial, economic,
social, moral, ethical, cultural, and legal transitions of evolution
caused by the modem biotechnological revolution. The global
society urgently demands formation of standardized multilateral
norms. These norms, of course, should equally consider all
biotechnologically relevant factors - intellectual property
protection, trade, environment, biodiversity, equity, and
sustainable development concerns - beyond the existing legal
regime to more effectually tackle emerging puzzles in the field of
biotechnology.
B. Debates
As already discussed, there have been severe pros and cons
72 Id.
73 WESTERLUND, supra note 9, at 7.
74 Id. at 7, 16.
75 MACMILLAN, supra note 1, at 138.
76 Id.
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regarding the new biotechnological development and its full
exploitation. This conflicting viewpoint is generally due to the
unforeseeability of future development and hidden risks which
will probably be caused by technological applications in the area
of biotechnology." While it is arguably paradoxical that
applications of modern biotechnology may have both promises
and perils, lots of contradictory debates are being widely spread
throughout the world. In the near future, transnational concerns
over whether traditional concepts of property rights that permit
private entities to exercise exclusive control over genetic resources
in the world can still be admissible, whether and on what grounds
countries may regulate international trade in biotechnologically
produced products, whether genetic engineering will give rise to
environmental harm through so called "genetic pollution," and
whether GMOs have adverse effects on global biological diversity
will be tremendous challenges to the world society.78
Advocates of biotechnology claim that agricultural
biotechnology can be applied to both crops and animals so as to
improve the quality and quantity of agricultural products.79
Ultimately, this may arguably contribute to enhancement of food
security. °  Globally speaking, this means that biotechnological
applications in agriculture can curtail the agricultural production
costs and lower the use of chemicals considered to have an
adverse effect on human health and the environment.8  In
particular, both lowering costs and increasing productivity in
agricultural production have very significant implications on
developing and the least developed countries because most of
them can meet their increasing demand for food by using
77 See INTRODUCTION TO INTELLECTUAL PROPERTY: THEORY AND PRACTICE, supra
note 3, at 587.
78 Murphy, supra note 1, at 47-48.
79 For example, they may be the crops with strengthened resistance to diseases,
insects, weeds, adverse weather, and pesticides, as well as the food of higher quality and
taste. See generally ARUP, supra note 1, at 216; see also Murphy, supra note 1, at 54-55.
80 Proponents of biotechnology particularly focus on the biotechnological ability to
increase food supply through higher yielding crops and improved animal husbandry
techniques including production of disease resistant organisms. MACMILLAN, supra note
1, at 138.
81 Murphy, supra note 1, at 55-56.
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environmentally sound agricultural biotechnology.82
Also, according to the proponents of biotechnology, products
of modem biotechnology may make greater contributions to the
advancement of medical science than they did before. Animals
and plants are being genetically engineered for medical research,
new drugs, new therapy, and reducing and curing diseases.83
These applications of biomedical engineering may help treat many
obstinate diseases more simply and effectively worldwide. This
development, in particular, makes it easier for developing
countries to gain access to specific medicines more inexpensively
and safely.84 Furthermore, through genetic engineering in the field
of biomedicine, the spread of major and common diseases in
developing countries, such as malaria, yellow fever,
trypanosomiasis, dengue, and other epidemics, can be more
effectively prevented. More recently, cloning techniques have
preeminently contributed to the developments of medicines,
diagnostic instruments, vaccines, and remedies for heart attack,
hemophilia, anemia, various cancers, AIDS, and other intractable
diseases in modem society.8 6  From the above-mentioned
biotechnological developments, mankind will be able to make
more forcible medicines to fight diseases such as cancer and
HIV/AIDS and protect public health.87
Critics of biotechnology, however, hold a skeptical view about
the enhancement of food security through biotechnology, and
simultaneously emphasize embryonic or unknown hazards to
sustainable development, agriculture, environmental biodiversity,
and public health.88 According to their arguments, even though it
82 Id. It is estimated that around 790 million people in developing countries are
chronically undernourished, and that by the year 2050, traditional plant-breeding
techniques without modem biotechnology may not meet increasing food production
necessary to feed the estimated world population of 9.4 billion. Id. at 47.
83 Id. at 51-52.
84 Id. at 53.
85 It is reported that reengineered insects have been developed for this purpose. Id.
at 53-54. According to a recent report, a mosquito was genetically transformed to
exterminate the mosquitoes carrying malaria. MACMILLAN, supra note 1, at 138.
86 LONG & D'AMATO, supra note 29, at 178.
87 INTRODUCTION TO INTELLECTUAL PROPERTY: THEORY AND PRACTICE, supra note
3, at 588.
88 MACMILLAN, supra note 1, at 138.
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is true that monoculture of genetically improved crops is deemed
to be more efficient in increasing food productivity and alleviating
starvation, due to the lack of biological diversity resulting from
monoculture and its characteristic susceptibility to catastrophic
diseases or weather, this kind of commercial exploitation of agro-
biotechnology may lead to diminished foodstuffs productions.8 9
Additionally, crops genetically engineered to be resistant to
herbicides and insecticides may result in an extravagant use of
herbicides or insecticides without sufficient consideration of
environmental harms.9" This effect may be rather a disaster to the
environment and human health by destroying the ecological
balance and degenerating biodiversity.9"
The controversies surrounding modem biotechnological
applications include consumer and ethical issues in addition to
environmentalist concerns about GMOs, public health, and
environmental protection. 92 The GMO issue is now in the middle
of the debates and concerns of a great number of non-
governmental organizations and civil society in this new
millennium.93 Generally speaking, the GMO industry, particularly
producers and companies in the U.S., has repeatedly stressed the
safety of genetically modified products.94 Nevertheless, farmers
and consumers, especially in Europe and developing countries,
who worry about not only genetically modified products'
unidentified hazards to human health and the environment, but
also its economic and social impacts, such as losses of market
dominance, competitive advantage, power of price control, and
increase of dependence on the U.S. biotechnology industry, are in
opposition to the extensive introduction of GMOs. 95
89 See generally ARUP, supra note 1, at 217-18; see also Cripps, supra note 1, at
122.
90 See generally Cripps, supra note 1, at 122.
91 Id. See also Murphy, supra note 1, at 59.
92 MACMILLAN, supra note 1, at 139.
93 HOEKMAN & KOsTECKI, supra note 32, at 456.
94 Id.
95 Id. For instance, the use of a "terminator gene" to prevent consumers'
regeneration of genetically developed seeds can allow producers to control the sale and
use of the seeds. However, Monsanto's use of this technology has been the target of
furious social criticism. Eventually, the application of the technology has been withheld.
ARUP, supra note 1, at 218.
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Farmers and consumers, in fear of currently unrevealed but
arguably intrinsic risks to both humans and the environment which
may be caused by "potential hazards with legs," insist that the
broad dissemination of GMOs into the environment without
proving environmental harmlessness be prevented.96 It is a critical
issue, not to be overlooked, that diffusion of GMOs can threaten
biological diversity because of its unanticipated, environmentally
unfriendly effects. 97 In addition, such national regulations and
measures concerning GMOs as labeling programmes or import
bans, prompted by consumers' requests, have increasingly become
a noteworthy cause of international trade disputes.98
As already noted, with regards to medical applications of
modern biotechnology, particularly cloning and transgenic
techniques, more profound questions of moral and ethical issues,
including identity or dignity of life, have proven to be seriously
debatable. 99  Internationally, patent applications for economic
property rights to - as well as commercialization,
commodification, and industrial use of - genetic resources,
genetic information, human genes, parts of human beings, and
higher life forms have had to be reviewed in terms of morality (or
ordre public), ethics, and human dignity. The scope of and ground
for granting or denying the intellectual property protection of
those genetic materials have been disputable and divergent among
different groups of people, research institutions, industrial entities,
regions, jurisdictions, and countries.100
To date, ethical, legal, and social implications of patenting
genetic resources and commercially exploiting genetic materials as
a commodity have been universally studied. In the future,
however, establishment of a legally and ethically general
consensus concerning the problems of commercial exploitation of
96 Murphy, supra note 1, at 57-59.
97 Cripps, supra note 1, at 126.
98 See HOEKMAN & KOSTECKI, supra note 32, at 456. See also Murphy, supra note
1, at 48.
99 See generally Cripps, supra note 1, at 123-26.
1o See generally ARUP, supra note 1, at 230-33; GRUBB, supra note 1, at 252-60.
See also BEYLEVELD & BROWNSWORD, supra note 28, at 196-205; Eisenberg, supra note
28, at 373-78; Galloux, supra note 28, at 361-71; Macklin, supra note 28, 129-37;
Marques, supra note 28, at 163-74; Marusyk & Athanassiadis, supra note 28, at 343-60;
Tangwa, supra note 28, at 275-8 1.
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genetic materials will probably be difficult. Additionally, their
legal status as a commodity will likely remain questionable for the
time being. Moreover, after the advent of Dolly the sheep, the
issues of the legitimacy and admissible scope of protection for
human DNA cloning techniques and their technological
applications have been the hottest potatoes in international
intellectual property regimes as well as the scientific world.1"'
Conclusively, the above altercations reflect our anxiety and/or fear
about the uncertainty and/or unpredictability of the results
stemming from the unnatural conversion of nature itself.
C. General Definition and Status
The term "sustainability," seldom clearly defined, is often used
in the discussion of emerging social concerns regarding
overpopulation and excessive consumption and their adverse
effects on environmental conservation.'0 2  "Development,"
modified by "sustainable" in the term "sustainable development,"
has a somewhat broad meaning which has covered at least four
related concepts - peace and security, economic development,
social development, and national governance that secures world
peace and development - in multilateral legal texts since the end
of World War 11.1"3 More generally, from the perspective of
general international law, the concept of sustainable development
has always been a fundamental issue in the discussion of
environmental law. This discussion has centered mostly on the
role of developing countries in environmental protection and the
relationships among the impacts upon ethics, economic
development, and effective environmental controls. Now, the
concept of sustainable development arguably ranks as "a candidate
emergent principle of general international law."'" More
specifically, international law in the field of sustainable
development has developed to embrace three aspects: international
101 LONG & D'AMATO, supra note 29, at 178-79.
102 Shardul Agrawala & Mark A. Cane, Sustainability: Lessons from Climate
Variability and Climate Change, 27 COLUM. J. ENvTL. L. 309, 309 (2002).
103 These elements have been increasingly mutually interdependent and interrelated.
For this general concept of "development," see generally John C. Dembach, Sustainable
Development: Now More Than Ever, 32 Envtl. L. Rep. (Envtl. L. Inst.) 10003, 10004-05
(2002).
104 IAN BROWNLIE, PRINCIPLES OF PUBLIC INTERNATIONAL LAW 287 (5th ed. 1998).
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cooperation, economic development, and the environment and
human rights, all of which have been interdependently treated." 5
Although there exists no general definition of sustainable
development accepted in international law or global society, its
theoretical background has a long history and the term itself has
emerged in treaties since the 1980s. °6  In particular, the
Brundtland Report adopted in the World Commission on
Environment and Development (WCED) °7 in 1987, provided what
is probably the most widely used, 1 8 frequently quoted, 109 and
generally cited"' definition relating to sustainable development.
According to the report, sustainable development is defined as:
"[D]evelopment that meets the needs of the present without
compromising the ability of future generations to meet their own
needs."
This report also urged that "'sustainable development' become
the foundation for all human economic activity, and thus that
concern for the environment and concern for lifting the standards
of the world's poor were inextricably linked.""11 This definition
has implications that represent the interrelationship between
development and the environment and between the needs of
present generations and those of successors in global society.'1 2
At the present stage, however, it is believed that under the
traditional concept of sustainable development, reductions in both
poverty and global environmental degradations have proven
largely unsuccessful. Poverty issues include a continuously
increasing gap between the rich and the poor. Environmental
issues cover health risks and environmental problems including
105 Philippe Sands, International Law in the Field of Sustainable Development:
Emerging Legal Principles, in SUSTAINABLE DEVELOPMENT AND INTERNATIONAL LAW
53, 53 (Winfried Lang ed., 1994).
106 Id. at 57-58.
107 WCED was created by the United Nations General Assembly in 1983. The
commission produced an influential document entitled "Our Common Future," generally
known as the Brundtland Report published in 1987. ANDREAS F. LOWENFELD,
INTERNATIONAL ECONOMIC LAW 304 (John H. Jackson ed., 2002).
108 Sands, supra note 105, at 58.
109 LOWENFELD, supra note 107, at 304.
110 Agrawala & Cane, supra note 102, at 309.
ill LOWENFELD, supra note 107, at 304.
112 Agrawala & Cane, supra note 102, at 309.
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exhaustion of natural resources such as plant and animal species. I 3
On this point, as the Brundtland Report clearly addressed, the four
basic elements of development - peace and security, economic
development, social development, and national governance - are
primarily related to environmental concerns and protection." 4
The one-sentenced expression in the Brundtland Report, the
first beginning to get significant international attention as a
definitive explanation of sustainable development,"5 however, did
not put an end to the debate regarding the general definition of
sustainable development. The concept of sustainable development
was further elaborated upon at the United Nations Conference on
Environment and Development (UNCED), or Earth Summit, held
in Rio de Janeiro in June 1992.16 This conference, by clearly
incorporating another element - environmental protection, the fifth
component of sustainable development - attempted to extend the
notion of sustainable development." 7 For example, the Rio
Declaration declared that every human being has the right to
health and productive life "in harmony with nature.""' 8
Additionally, Agenda 21 affirmed that protection of the
environment and resources for the benefit of future generations
can be achieved through "socially responsible economic
development."" 9 This approach suggests that a new formula is
needed for understanding sustainable development, triangulating
three components - the environment, economy, and equity. 21
113 Dernbach, supra note 103, at 10005-06.
114 Id. at 10006-07.
115 Id. at 10003.
116 Although legally nonbinding, two texts, which were adopted at the UNCED, the
Rio Declaration on Environment and Development, consisting of statements of 27
principles for sustainable development, and Agenda 21, which is a global plan of action
for sustainable development, were adopted by attending nations agreeing to promote
sustainable development at the international as well as the national level. Id.
117 Id. at 10007.
118 United Nations Conference on Environment and Development: Rio Declaration
on Environment and Development, June 14, 1992, Principle 1, 31 I.L.M. 874, 876
[hereinafter The Rio Declaration]
119 United Nations Conference on Environment and Development, Agenda 21:
Programme of Action for Sustainable Development, Agenda 21, ch. 8.7, U.N. Doc.
A/Conf. 151/4 (1992), available at http://www.un.org/esa/sustdev/documents
/agenda2 1/english/agenda2 1 chapter8.htm [hereinafter Agenda 21].
120 Dembach, supra note 103, at 10008.
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Since this landmark on international environmental legal progress,
the concept of sustainable development has acquired a status of
"grundnorm" in global environmental law. 2 '
Concurrently, in the international environmental legal
framework, equity issues concerning "environmental justice," a
source of severely contradictory arguments in considering
sustainable development, have increasingly emerged. In
international environmental legal instruments, equity concerns
have driven traditional concepts of equity'22 to be challenged and
engendered a new kind of equity notion.' Traditionally, states
have the sovereign right to use and control natural resources
within their territorial jurisdiction, and first claimants over
resources not covered by national sovereignty have the exclusive
rights to exploit them. However, the more recent meaning of
equity in environmental law encompasses new issues such as the
"allocation of natural resources" and "responsibility and liability
for pollution."'24
Therefore, the general principles that provide a philosophical
basis for sustainable development consist of principles of
intergenerational equity, sustainable use, equitable use, and
integration. These are now considered the four key components of
sustainable development. 25  However, the legal status of each
principle will vary according to its normative character: whether it
is based on or reflects customary law, whether it is a new or
emerging international legal concept, or whether it is a simple
intention to affect future conduct. 26  In conclusion, the general
121 "Grundnorm" means basic norm in English, which, in the context of
international environmental law, is the fundamental rule of law for all international
environmental legal validity or legitimacy. Lakshman D. Guruswamy, Sustainable
Agriculture: Do GMOs Imperil Biosafety?, 9 IND. J. GLOBAL LEGAL STUD. 461, 463
(2001).
122 The notion of equity in public international law is used in the sense of
considering fairness, reasonableness, and policy which is often necessary for the sensible
application of the rules of law. It may also be an important element, as a supplementary
part of law or judicial reasoning, in international judicial decisions. BROWNLIE, supra
note 104, at 25-26.
123 Weiss, supra note 45, at 17.
124 Id. at 18.
125 Sands, supra note 105, at 57-61.
126 Id. at 57-58.
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definition of sustainable development, to the extent that
international law recognizes the concept of sustainable
development, should principally approve the following interests:
27
(a) the need to take into consideration the needs of present and
future generations;
(b) the acceptance, on environmental protection grounds, of
limits placed upon the use and exploitation of natural resources;
(c) the role of equitable principles in the allocation of rights and
obligations; and
(d) the need to integrate all aspects of environment and
development.
At the same time, in the modern context, we cannot ignore
relevant trade factors in considering sustainable development. As
the Rio Declaration and Agenda 21 described, interests of
international trade liberalization and sustainable development have
been mutually connected. 28  The Rio Declaration calls on
countries "to promote a supportive and open international
economic system that would lead to economic growth and
sustainable development in all countries. .,,2' Agenda 21 asks
states to promote trade liberalization to support sustained
economic development and "to make international trade and
environment policies mutually supportive in favour of sustainable
development. '' 30
Particularly after the launch of the WTO legal system,
sustainable development has been a core issue in the discussion
concerning the interaction between trade and the environment.
During this discussion, arguments for changing international trade
rules and practices to improve the environment and promote
sustainable development have been continuously raised. The
WTO, a newly established comprehensive multilateral trading
system, hopes to achieve harmonization between trade and the
environment to enhance the concept of sustainable development.'
127 Id. at 62.
128 Dernbach, supra note 103, at 10009.
129 The Rio Declaration, Principle 12, supra note 118, at 878.
130 Agenda 21, chs. 2.9(a), 2.21(a), supra note 119, available at
http://www.un.org/esa/sustdev/documents/agenda2 l/english/agenda2l chapter2.htm.
131 See Jennifer Schultz, Current Development: The GATT/WTO Committee on
Trade and the Environment - Toward Environmental Reform, 89 AM. J. INT'L L. 423,
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The WTO, explicitly acknowledging sustainable development as a
policy objective, requires member states to recognize the
importance and legitimacy of environmental protection132
According to the WTO Appellate Body, provisions of the GATT
should be interpreted in light of "the objective of sustainable
development."' 33
However, these contradictory policy goals - trade
liberalization, environmental protection, and sustainable
development - still remain somewhat incompatible.' Thus, a
more integrated policy approach to make trade liberalization and
environmental protection programs reciprocally supportive to
sustainable development is needed. More recently, it has been
observed that the essence of sustainable development is
increasingly sought in the international trade context. For
example, the WTO Appellate Body, in principle, approves
countries' rights to environment-related trade restriction measures
on the ground that such a conservation policy is compatible with
437-39 (1995).
132 See General Agreement on Tariffs and Trade - Multilateral Trade Negotiations
(The Uruguay Round): Agreement Establishing the Multilateral Trade Organization
[World Trade Organization], Dec. 15, 1993, Preamble, 33 I.L.M. 13, 15 [hereinafter
WTO Agreement].
133
They must be read by a treaty interpreter in the light of contemporary
concerns of the community of nations about the protection and conservation
of the environment. While Article XX was not modified in the Uruguay
Round, the preamble attached to the WTO Agreement shows that the
signatories to that Agreement were, in 1994, fully aware of the importance
and legitimacy of environmental protection as a goal of national and
international policy. The preamble of the WTO Agreement - which informs
not only the GATT 1994, but also the other covered agreements - explicitly
acknowledges 'the objective of sustainable development.'
WTO Report of the Appellate Body, United States-Import Prohibition of Certain Shrimp
and Shrimp Products, WT/DS58/AB/R paras. 129-30 (Oct. 12, 1998), available at
http://www.sice.oas.org/Dispute/wto/58abr.asp [hereinafter WTO Report on U.S.
Prohibition on Shrimp]. "From the perspective embodied in the preamble of the WTO
Agreement, we note that the generic term 'natural resources' in Article XX(g) is not
'static' in its content or reference but is rather 'by definition, evolutionary."' Id.
134 Sanford E. Gaines, Triangulating Sustainable Development: International Trade,
Environmental Protection, and Development, 32 Envtl. L. Rep. (Envtl. L. Inst.) 10318,
10318-19 (2002). For a short history of trade and environment issues from 1990 to
2001, see generally id. at 10327-31 (2002).
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protection of endangered species and promotion of biodiversity. 35
In this respect, we can find the phenomenon of a sustainable
development-oriented international trade regime.
136
For the present, since the intellectual property protection
system was incorporated into the WTO legal framework through
the TRIPs Agreement, provisions with the aim of protecting
biodiversity by international intellectual property protection rules,
beyond the conventional trade and environmental legal regime,
can play a critical role in promoting sustainable development. For
example, the TRIPs Agreement Article 27.2131 offers some
incentives for conservation schemes and supports biodiversity
protection. 138 Thus, trade rules on intellectual property protection
of biotechnology such as the TRIPs Agreement can and should be
a supportive element for sustainable development.
In conclusion, in modem society, from the standpoint of
sustainable development, the environment itself is deemed a
fundamental source of human welfare, and natural capital -
including both renewable and nonrenewable resources, living
organisms, and ecological systems - has to be protected for the
benefits of present and future generations. In addition, sustainable
development should be beneficial for protection and restoring the
environment as well as removing large-scale poverty.'39 This
notion should be a decisive constraint on human activities
artificially altering nature itself.
Now, despite the absence of a globally accepted consensus on
environmental principles or policies relating to sustainable
environments, it should be noted that "[flitting biotechnology
regulation into the context of sustainable development is an
135 WTO Report on U.S. Prohibition on Shrimp, supra note 133, paras. 130-3 1.
136 Gaines, supra note 134, at 10331.
137 "Members may exclude from patentability inventions, the prevention within their
territory of the commercial exploitation of which is necessary to protect order public or
morality, including to protect human, animal or plant life or health or to avoid serious
prejudice to the environment .... Agreement on Trade-Related Aspects of Intellectual
Property Rights, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade
Organization art. 27.2, LEGAL INSTRUMENTS-RESULTS OF THE URUGUAY ROUND vol. 31,
33 I.L.M. 81 (1994), available at http://www.wto.org/english/tratop_e/tripse/
t agm3_e.htm [hereinafter TRIPS Agreement].
138 Schultz, supra note 131, at 436.
139 Dernbach, supra note 103, at 10009.
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important international goal, both from an environmental and
economic perspective.' ' 40  Therefore, "encouragement of the
development and diffusion of environmentally friendly
technologies' 4' should be more emphasized in both the contexts
of economically and environmentally sustainable development.
On this point, modem biotechnology, as one of the keys to
sustainable development in the twenty-first century, represents an
economic-environmental dilemma in our global community.
III. Evolutionary Approach to Modern Biotechnology and
Sustainable Development
A. Relevant Rules
1. Sources ofLaw
In general, Article 38(1) of the Statute of the International
Court of Justice (ICJ Statute) has been primarily referred to in
discussions of what the international law is'42 or what the sources
of international law are.'43 Although the article itself does not
include the term "sources" and does not explicitly enumerate the
"sources of law," it is generally considered a "complete statement
of the sources of international law."'" The provisions read as
follows:
140 On the contrary, it is pointed out that, in the process of policy and rule making in
the U.S., sustainable yield, maintenance of biological diversity, internationalization of
environmental costs of economic activity through liability or administrative rule,
transparency of policy, and public participation are generally accepted as factors
supportive of creating environmental equilibrium or balance for sustainability. George
Van Cleve, Regulating Environmental and Safety Hazards of Agricultural Biotechnology
for a Sustainable World, 9 WASH. U. J.L. & POL'Y 245, 251-57 (2002).
141 John Gerard Ruggie, Trade, Sustainability and Global Governance, 27 COLUM.
J. ENVTL. L. 297, 301 (2002).
142 "Article 38 of the Statute of the International Court of Justice contains ... the
traditional statement of those of sources." BARRY E. CARTER & PHILLIP R. TRIMBLE,
INTERNATIONAL LAW 3 (3rd ed. 1999).
143 See David Palmeter & Petros C. Mavroidis, The WTO Legal System: Sources of
Law, 92 AM. J. INT'L L. 398, 398 (1998). See also BROWNLIE, supra note 104, at 3; see
generally; Louis HENKIN, ET AL., INTERNATIONAL LAW: CASES AND MATERIALS 51-52,
54-126 (3rd ed. 1998).
144 BROWNLIE, supra note 104, at 3.
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Article 38
1. The Court, whose function is to decide in accordance with
international law such disputes as are submitted to it, shall
apply:
a. international convention, whether general or particular,
establishing rules expressly recognized by the contesting states;
b. international custom, as evidence of a general practice
accepted as law;
c. the general principles of law recognized by civilized nations;
d. subject to the provisions of Article 59,145 judicial decisions
and the teachings of the most highly qualified publicists of the
various nations, as subsidiary means for the determination of
rules of law.
In the case of international trade of all kinds of genetically
modified products made possible by biotechnology, WTO rules, as
rules of general international law or a legal framework for global
trade relations constituting "lex specialis vis-A-vis certain rules of
international law,"'146 obviously apply. Consequently, in
international trade disputes regarding issues of domestic public
health, safety, and environmental protection caused by
biotechnological products such as GMOs, the WTO and its
annexed relevant multilateral trade agreements primarily apply.
For example, general exceptions under the GATT 1994, General
Agreement on Trade in Services (GATS), Agreement on
Application of Sanitary and Phytosanitary Measures (SPS
Agreement), Agreement on Technical Barriers to Trade (TBT
Agreement), and TRIPs Agreement have substantial relevance.147
Those aforementioned instruments, dealing with trade in
145 "The decision of the Court has no binding force except between the parties and
in respect of that particular case." I.C.J. Statute art. 59, available in SHABTA ROSENNE,
THE LAW AND PRACTICE OF THE INTERNATIONAL COURT, 1920-1996, VOLUME III 1627
(3d. ed. 1997).
146 Therefore, the WTO rules have basic policy objectives of regulating the trade
between countries and trade liberalization. JOOST PAUWELYN, The Role of Public
International Law in the WTO: How Far Can We Go?, in NEW DIRECTIONS IN
INTERNATIONAL ECONOMIC LAW: ESSAYS IN HONOR OF JOHN H. JACKSON 535, 539-40
(Marco Bronckers & Reinhard Quick ed., 2000).
147 MACMILLAN, supra note 1, at 8. See also John S. Applegate, The Prometheus
Principle: Using the Precautionary Principle to Harmonize the Regulation of
Genetically Modified Organisms, 9 IND. J. GLOBAL LEGAL STUD. 207, 237-40 (2001).
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goods, services and intellectual property protection within the
framework of the WTO legal system, can manifestly fall under the
"particular international conventions.., expressly recognized by
the contesting states '  to which Article 38(l)(a) of the ICJ
Statute refers.'49 Thus, within the context of the WTO, basic legal
sources regulating biotechnology and its possibly resulting
products are texts of the relevant agreements and provisions
themselves, 150 which are the most preferentially and directly
applicable.15' The WTO Appellate Body also recognizes that the
words and texts of the treaty are the basis for the interpretation, 5 '
and that the textual interpretation is the most appropriate.'53
Of course, strictly speaking, the WTO Agreement and its
annexed multilateral agreements were not established primarily for
protecting the environment or promoting sustainable development,
but to achieve trade liberalization based on free trade values and
market-oriented principles. As the preamble to the WTO
Agreement elucidates, however, 154 the WTO explicitly recognizes
148 Professor Pauwelyn, personally, argues that the WTO law is "just a branch of
public international law" which creates "international legal obligations that are part of
public international law." Thus, in his opinion, WTO rules are general or "les generalis"
at least in dealing with the trade relations between countries. PAUWELYN, supra note
146, at 538-40. However, in the context of the ICJ Statute, it is apparent that the WTO
Agreement and its annexed agreements are a sort of "particular international
conventions" binding the member states.
149 Palmeter & Mavroidis, supra note 143, at 398.
i5o Id.
151 Among other things, international conventions and custom are obviously
important. The former, however, has a priority because it represents not general
applications of rules but specifically reciprocal obligations between contracting parties.
The priority of application of the sources in the Article 38(1) of the ICJ Statute is simply
subject to the order (a) to (d) in that clause. BROWNLIE, supra note 104, at 3-4.
152 "Article 31 of the Vienna Convention provides that the words of the treaty form
the foundation for the interpretive process: 'interpretation must be based above all upon
the text of the treaty."' WTO Report of the Appellate Body, Japan-Taxes on Alcoholic
Beverages, WT/DS8/AB/R, section D, (Oct 4, 1996), available at flp://ftp.sice.
oas.org/pub/sice/wtowo7/wto5_wo7.exe [hereinafter WTO Report on Japan Taxes].
153 "The proper interpretation of the Article is, first of all, a textual interpretation."
Id. § G.
154 "The Parties to this Agreement... while allowing for the optimal use of the
world's resources in accordance with the objective of sustainable development, seeking.
. to protect and preserve the environment ...." WTO Agreement, supra note 132, at
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the connection between promoting free trade and securing
sustainable development as well as protecting the environment.55
The TRIPs Agreement was reached initially for the purpose of
protecting personal creative products and regulating trade of
pirated or counterfeited goods according to the WTO's trade
liberalization principle. 156 However, through the incorporation of
agriculture, health, culture, and human life provisions into the
TRIPs Agreement,'5' use and application of modem biotechnology
likewise have closely relevant implications on sustainable
development in the context of the WTO legal system. Therefore,
as far as the issues concerning modem biotechnology and its
sustainable use are concerned, the relevant WTO provisions and
rules should be interpreted and applied together.
The WTO rules, however, do not exhaust international
conventions as a source of law applicable to the issues of
biotechnology. Rather, the more specific rules of international law
are likely to be highly related. These include preexisting treaty
law confirmed by the WTO rules'58 and non-WTO rules that
already existed when the WTO treaty was concluded (on April 15,
1994) or have been created subsequent to the WTO treaty (post-
April 1994), all of which are relevant to and may have a certain
impact on the WTO rules.'59 Moreover, the Vienna Convention on
the Law of Treaties (Vienna Convention) states that "any relevant
rules of international law applicable in the relations between the
parties" together with the context of the treaty itself should be
155 In addition, WTO has several institutions such as the Committee on Trade &
Environment that treat trade and environment issues. According to recent developments,
the Dispute Settlement Body of the WTO also tends to be favorable to the environmental
protection issues when tensions or clashes between trade and the environmental concerns
occur. Besides these phenomena, many environment-related provisions are dispersed in
the WTO multilateral trading agreements such as the GATT 1994 Articles XX (b) and
(g), TRIPs Agreement arts. 27.2, 27.3 and 3 1(b), SPS Agreement arts. 2.2 and 2.3, and
TBT Agreement, etc. MACMILLAN, supra note 1, at 1-2, 7-41.
156 See TRIPS Agreement Preamble, supra note 137.
157 ARUP, supra note 1, at 13.
158 For example, certain parts of the World Intellectual Property Organization
(WIPO) conventions were incorporated into the TRIPs Agreement.
159 As a result, the WTO panel has to scrutinize these factors as a legal source to be
applied to resolve the WTO claims submitted by the parties. PAUWELYN, supra note
146, at 540-41, 559-60.
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taken into account. 160  The Uruguay Round Understanding on
Rules and Procedures Governing the Settlement of Disputes
(DSU) directs the "panels to address the relevant provisions in any
covered agreement or agreements cited by the parties to the
dispute. 161
The fact that these other relevant international agreements are
referred to in the covered agreements of the WTO or the parties
concerned are also contracting parties to the WTO legal system
makes it possible for them to be sources of the WTO law. 162
Among other things, multilateral environmental agreements
(MEAs) may be considered as significantly relevant rules,
agreements, or provisions in the context of biotechnology. After
the 1990s, in particular, the relationship between the MEAs and
the GATT and WTO has been considerably discussed in the WTO
jurisprudence.'63 Until now, there have been no MEA provisions
appearing to invalidate the WTO concessions. Nonetheless,
MEAs, as subsequent agreements or arguably subsequent
practices 64 having an interpretative significance or possibly
binding effects, may be taken into account in interpreting relevant
provisions in the WTO legal regime.'65
Similarly, the WTO Appellate Body suggests a new model for
the interpretation of the GATT by taking an implicit attitude to
understand the GATT provisions within a broader framework of
international law and policy relevant to the environment and
development.166 It also evidently has recourse to the relevant
160 The Vienna Convention on the Laws of Treaties, May 23, 1969, art. 31(3)(c), 8
I.L.M. 679 (1969) [hereinafter The Vienna Convention].
161 Dispute Settlement Rules: Understanding on Rules and Procedures Governing
the Settlement of Disputes, Marrakesh Agreement Establishing the World Trade
Organization, Annex 2, art. 7.2, THE LEGAL TEXTS: THE RESULTS OF THE URUGUAY
ROUND OF MULTILATERAL TRADE NEGOTIATIONS 354 (1999), 1869 U.N.T.S. 401, 33
I.L.M. 1226 (1994) [hereinafter DSU].
162 Palmeter & Mavroidis, supra note 143, at 409.
163 The main issue has been potential conflict between the MEAs and trade
obligation. James Cameron & Kevin R. Gray, Principles of International Law in the
WTO Dispute Settlement Body, 13 INT'L & COMp. L.Q. 248, 263-66 (2001).
164 The Vienna Convention arts. 31(3)(a) and (b), supra note 160, at 692.
165 Cameron & Gray, supra note 163, at 265-66.
166 Robert Howse, The Appellate Body Rulings in the Shrimp/Turtle Case: A New
Legal Baseline for the Trade and Environment Debate, 27 COLUM. J. ENVTL. L. 491, 521
(2002).
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MEAs in the WTO lawsuit.167 By explicit reference to and
adoption of the relevant MEAs in interpreting the WTO law and
resolving the disputes, the WTO is trying to not only make up the
gap between trade and the environment, but also open the
possibility of incorporating environmental concerns into the WTO
legal system.'68
The texts of the above-mentioned international instruments,
however, do not cover all sources of law applicable to the issues
concerning biotechnology. Rather, the texts themselves are just
"first of all."' 169  Particularly in the contexts of both intellectual
property protection of biotechnology and its implication for
sustainability, other transnational agreements at the regional as
well as the global level beyond the WTO legal framework may be
of equal importance. Additionally, according to the subparagraphs
of Article 38(1) of the ICJ Statute, former and subsequent
practices including dispute resolution reports of the GATT and
WTO, custom, general principles of law, and teachings of highly
qualified publicists are possible sources of law 7 ' applicable to
modem biotechnology issues.
2. Trade in GMOs and Multilateral Trade Agreements
a. The GATT 1994 and the SPS and TBTAgreements
When the issue arises of whether a certain trade restrictive
measure on GMOs' 7' imposed by a WTO member state is contrary
167 In interpreting the modem meaning of the term "exhaustible natural resources"
in the GATT 1994 Article XX(g), the WTO Appellate Body addresses, as relevant
conventions and declarations, the Unite Nations Convention on the Law of the Sea,
United Nations Convention on Biological Diversity, Agenda 21, Resolution on Assistant
to Developing Countries adopted in conjunction with the Convention on the
Conservation of Migratory Species of Wild Animals and Appendix 1 of the Convention
on International Trade in Endangered Species of Wild Fauna and Flora. See WTO
Report on U.S. Prohibition on Shrimp, supra note 133, paras. 130, 132.
168 Cameron & Gray, supra note 163, at 266-67.
169 Palmeter & Mavroidis, supra note 143, at 399.
170 Id.
171 In practice, products from genetic resources such as the patented
biotechnological inventions, pharmaceutical products, and agricultural varieties have an
obvious implication on trade. MACMILLAN, supra note 1, at 117. These products and
resources are evidently goods that can be traded between countries. Traditionally, trade
in goods has been regulated by the GATT provisions.
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to general obligations under the GATT (such as the obligations of
most-favoured nation treatment, 172  national treatment, 7 3  or
prohibition of quantitative restrictions),174 relevant provisions in
the GATT 1994 have direct applicability. 75
Apart from the GATT 1994, both the SPS Agreement and the
TBT Agreement may affect regulation of biotechnological
products. 176 Although there is a basic difference between the SPS
Agreement and the TBT Agreement in that the former seeks to
limit health restrictions while the latter attempts to limit technical
restrictions, 77 both of them have a direct relation to the
controversy and measures concerning GMOs, such as the issue of
labeling genetically modified products.'78 In particular, the SPS
Agreement is most applicable to measures relating to biodiversity
protection, agriculture, and agricultural biotechnology. 179 While it
is not yet certain whether the WTO Dispute Settlement Body
would directly apply the agreements to the GMO debates, 8' they
are, at least at the international level, playing an important role in
172 GATT 1994: General Agreement on Tariffs and Trade 1994, Apr. 15, 1994,
Marrakesh Agreement Establishing the World Trade Organization, Annex 1A, art. I, THE
LEGAL TEXTS: THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE
NEGOTIATIONS 17 (1999), 1867 U.N.T.S. 187, 33 I.L.M. 1153 (1994) [hereinafter GATT
1994].
173 Id. art. III.
174 Id. art. XI.
175 Besides the GATT 1994 articles I, II, and XI, general exceptions clauses of
article XX would be looked to in considering whether the measures in question arguably
violating the substantive articles can be justified under those clauses. Brett Grosko,
Genetically Engineering and International Law: Conflict or Harmony? An Analysis of
the Biosafety Protocol, GA TT, and the WTO Sanitary and Phytosanitary Agreement, 20
VA. ENVT'L L.J. 295, 306 (2001).
176 MACMILLAN, supra note 1, at 139.
177 Id. at 9.
178 Julie Teel, Regulating Genetically Modified Products and Processes: An
Overview ofApproaches, 8 N.Y.U. ENvTL. L.J. 649, 683, 686 (2000).
179 John H. Barton, Biotechnology, the Environment, and the International
Agricultural Trade, 9 GEO. INT'L ENVTL. L. REv. 95, 101 (1996).
180 As of April 2000, it is reported that there have been three WTO panels and
Appellate Body decisions resolved under the SPS Agreement. Two cases included
"sanitary" measures surrounding food safety and fishery ecology and the remaining one
bore on "phytosanitry" measures centering on agricultural diseases. Steve Charnovitz,
The Supervision of Health and Biosafety Regulation By World Trade Rules, 13 TUL.
ENVTL. L.J. 271, 273-75 (2000).
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the development and adoption of food safety and labeling
standards. 1
81
The TBT Agreement is normally concerned with labeling
requirements and nutritional issues regarding agricultural
products, and the SPS Agreement may also apply to some
packaging and labeling issues, if directly related to health or food
safety concerns. 8 2 The GATT 1994 provisions, as a defense in an
SPS dispute, may not be preferred to the SPS Agreement
provisions since the disciplines in the SPS Agreement are more
rigid than those in the GATT 1994.83 With respect to trade in
biotechnological products, when provisions of both agreements
similarly apply, the SPS Agreement will have a priority over the
TBT Agreement (similar to the relationship between the GATT
1994 and the SPS Agreement). 84 The SPS Agreement "explicates
and tightens" the GATT Article XX exceptions, and the TBT
Agreement, mainly applying to labeling programmes, "can be seen
as a subset" of the SPS Agreement.
1 85
b. The GATS and TRIPs Agreement
The GATS, as in the case of the general exceptions clauses in
the GATT 1994, has a provision permitting violation of general
obligations in the GATS when it is necessary to protect human,
animal, or plant life or health.186 The scope and extent of
interpretation of the two provisions are very similar.187
18, Teel, supra note 178, at 683-84.
182 See George E. C. York, Global Food, Local Tastes and Biotechnology: The New
Legal Architecture of International Agriculture Trade, 7 COLUM. J. EUR. L. 423, 457
(2001). See also Teel, supra note 178, at 687.
183 Chamovitz, supra note 180, at 273.
184 "The TBT Agreement does not supervise any measures covered by the SPS
Agreement." Id. at 277. "In practice, as is the case with GATT Article XX(b), the more
recent SPS Agreement has overshadowed the TBT Agreement in the current dialogue on
transnational biotechnology trade." York, supra note 182, at 457.
185 Applegate, supra note 147, at 237.
186 GATS: General Agreement on Trade in Services, Apr. 15, 1994, Marrakesh
Agreement Establishing the World Trade Organization, Annex 11B, art. XIV(b), THE
LEGAL TEXTS: THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE
NEGOTIATIONS 284 (1999), 1869 U.N.T.S. 183, 33 I.L.M. 1167 (1994) [hereinafter
GATS].
187 MACMILLAN, supra note 1, at 8-9.
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The TRIPs Agreement is, with its implications of multilateral
regulations for biotechnology, trying to converge and reinforce
intellectual property protection based on a trade-oriented
approach. As for patents on biotechnological inventions, the
TRIPs Agreement provisions are basically taking a dual structure:
first "it requires members to make patents available for any
inventions, whether products or processes, in any field of
technology" covering highly advanced modem biotechnology; and
second, certain national exclusions from patentability.'88 However,
the fact that the TRIPs Agreement does not expressly address
genetically modified products may result in inconsistent
interpretations, particularly concerning patents on living
organisms, genetically engineered gene materials, or the legal
status of GMOs. Moreover, incorporation of intellectual property
issues into the trade-oriented TRIPs Agreement has led to
ambiguity in interpretation of the treaty norms.'89
c. The GA TT and WTO Practices
As the subparagraphs of Article 38(1) of the ICJ Statute states,
the national and international practices, custom, general principles
of law, and teachings of highly qualified publicists may be
relevant rules' 90 applicable to the issues surrounding modem
biotechnology. Among them, practices including judicial
decisions of the GATT or WTO, as the WTO Agreement evidently
addresses,' 91 may have the potential to be applied to the
interpretation of the relevant provisions. When it is fully taken
into consideration that the history of the interpretation and
application of intellectual property protection of biotechnology in
the GATT/WTO legal framework is so short, the prior practices
will be a particularly useful indicator for future interpretation of
the provisions in the TRIPs Agreement.
188 ARUP, supra note 1, at 238-40; TRIPS Agreement arts. 27.1, 27.2, and 27.3,
supra note 137.
189 Murphy, supra note 1, at 68-69.
190 Palmeter & Mavroidis, supra note 143, at 399.
191 "Except as otherwise provided under this Agreement or the Multilateral Trade
Agreements, the WTO shall be guided by the decisions, procedure and customary
practices followed by the CONTRACTING PARTIES to GATT 1947 and the bodies
established in the framework of GATT 1947." WTO Agreement art. XVI. 1, supra note
132, at 1152.
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In that sense, the two recently published WTO declarations
resulting from the WTO Ministerial conference in Doha, Qatar -
the WTO Ministerial Declaration'9 2 (Doha Declaration) and the
Declaration on the TRIPs Agreement and Public Health'93 -
deserve special attention in our discussion of whether their legal
status can be subsequent practices or custom, which may exert
substantial influences on future practices in relation to
biotechnology. '94
3. Multilateral Environmental Agreements
Again, the fact that other relevant international agreements
outside the framework of the WTO are referred to in the covered
agreements of the WTO and the contracting parties to the other
international agreements are also member states to the WTO
makes it possible for them to be sources of law'95 on modem
biotechnology issues. Beyond the WTO legal framework, in fact,
there are diverse and numerous international organizations and
agreements tackling GMO issues. 9 6  Among them, particularly
from the perspectives of biotechnology and GMOs, the United
Nations Convention on Biological Diversity (CBD) and the
Cartagena Protocol on Biosafety to the CBD (Biosafety Protocol)
seem to be the most important and directly relevant.
The CBD 97 intends not only to conserve biological diversity
192 World Trade Organization (WTO) - Doha Ministerial 2001: Ministerial
Declaration, adopted on 14 November 2001, WT/MIN(01)/DEC/1, 20 Nov. 2001, 41
I.L.M. 746 (2002), available at www.wto.org/english/thewto_e/ministe/minole/
mindecl e.htm.
193 World Trade Organization (WTO) - Doha Ministerial 2001: Declaration on the
TRIPS Agreement and Public Health, adopted on 14 November 2001,
WT/MIN(01)/DEC/2, 20 Nov. 2001, 41 1.L.M. 755 (2002), available at
www.wto.org/engligh/thewto e/minist-e/minole/mindecl trips e.htm [hereinafter the
Declaration on the TRIPS Agreement and Public Health].
194 See James Thuo Gathii, The Legal Status of the Doha Declaration on TRIPS and
Public Health Under the Vienna Convention on the Law of Treaties, 15 HARV. J.L. &
TECH. 291 (2002). See also Amir Attaran, The Doha Declaration on the TRIPS
Agreement and Public Health, Access to Pharmaceuticals, and Options Under WTO
Law, 12 FORDHAM INTELL. PROP. MEDIA& ENT. L.J. 859 (2002).
195 See Cameron & Gray, supra note 163.
196 York, supra note 182, at 462-65.
197 The CBD is arguably one of the international legal instruments in which the
international law in the field of sustainable development is addressed in an integrated
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and promote sustainable use of biodiversity components, but also
to share the benefits arising out of utilization of genetic
resources.1 98 In particular, with regard to biotechnology, the CBD
contains provisions regulating access to genetic resources,
intellectual property rights protecting patents on biotechnologies,
and technology transfer facilitating equitable sharing of interests
derived from biodiversity. 99 Thus, the CBD can be deemed an
international scheme for conservation and use of global biological
resources in a sustainable manner in company with recognition of
the relationship between intellectual property rights and use of
genetic resources."'
The subsequently concluded Biosafety Protocol is a result of
specific attempts to regulate living modified organisms (LMOs),
which may cause negative effects to the environment as well as
human health.20 ' However, it is pointed out that the Biosafety
Protocol has an immanently weak point of applying only to trade
in LMOs, in contrast with the original intent to establish a
comprehensive global system dealing with the relevant
problems.0 2
4. International Instruments for Intellectual Property
Protection
To date, several international or regional agreements have
been established regarding intellectual property protection of
biotechnological inventions. In the contexts of modern
manner. Sands, supra note 105.
198 Convention on Biological Diversity, Rio de Janeiro on 5 June 1992, art. 1, 1760
U.N.T.S. 146, 146 (1993) [hereinafter CBD].
199 Sheehan, supra note 34, at 148.
200 See CBD art. 16, supra note 198, at 152-53; MACMILLAN, supra note 1, at 119.
201 Stephen McCaffrey, Biotechnology: Some Issues of General International Law,
14 TRANSNAT'L LAW. 91, 94-95 (2001). According to Article 1 of the Biosafety
Protocol, the stated objective of it is "to contribute to ensuring an adequate level of
protection in the field of the safe transfer, handling and use of living modified organisms
resulting from modem biotechnology that may have adverse effects on the conservation
and sustainable use of biological diversity, taking into account risks to human health."
Cartagena Protocol on Biosafety to the Convention of Biological Diversity, Jan. 29,
2000, art. 1, 39 I.L.M. 1027, 1027 (entered into force Sept. 11, 2003), available at
http://www.biodiv.org/doc/legal/cartagena-protocol-en.pdf [hereinafter the Biosafety
Protocol].
202 McCaffrey, supra note 201, at 95.
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biotechnology and sustainable development, of course, these
instruments have a direct applicability. The International
Convention for the Protection of New Varieties of Plants (or the
International Union for the Protection of New Varieties of Plants)
(UPOV203) grants plant variety rights to plant breeders,
concurrently focusing on the balance between the owners' rights
and others' need to have access to and use of the varieties.20 4 This
balance is sought in terms of farmers' and breeders' rights.20 5 The
UPOV has a strong point in that it covers both developed and
developing countries, not merely a few major developing
countries, mainly because it recognizes the sui generis system for
the protection of plant varieties. 2 6 Therefore, this convention has
substantially influenced the formation of national laws in that
field.2 °7
The Budapest Treaty on the International Recognition of the
Deposit of Microorganisms for the Purposes of Patent Procedure
of 1977 (Budapest Treaty), which became effective in 1980 and
with which 48 countries, including the majority of developed
countries, have been affiliated as of July 2000,208 may also have an
important meaning to biotechnological sustainability. 209  The
establishment of an internationally recognized depository system
for biological materials like microorganisms and the sustenance of
breeding are the main objectives of the treaty. 210 This standardized
scheme for the deposit of microorganisms, which executes
disclosure of patented materials and access to deposited
materials, 211 in a certain sense, contribute to the conservation or
promotion of biological diversity.
203 This convention is commonly called the UPOV Convention, the French acronym
for the treaty (Union Internationale pour la Protection des Obtentions Vdgdtales). PAUL
GOLDSTEIN, INTERNATIONAL INTELLECTUAL PROPERTY LAW: CASES AND MATERIALS 103
(2001) [hereinafter UPOV].
204 ARUP, supra note 1, at 234.
205 MACMILLAN, supra note 1, at 49.
206 Id.
207 UPOV, supra note 203, at 311.
208 See generally WATAL, supra note 1, at 157; see also GRUBB, supra note 1, at
228.
209 See, e.g., Cripps, supra note 1, at 122-23.
210 GRUBB, supra note 1, at 228.
211 WATAL, supra note 1, at 157-60.
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Although they are only regionally applicable, the Convention
on the Grant of European Patents 212  (or European Patent
Convention) (EPC) and the European Biotechnology Invention
Directive213  (European Directive) provide us with useful
interpretational tools for determining the reasonable scope of
intellectual property protection of biotechnology to assist
sustainable development. Both are in part contriving to protect a
certain category of social order and environmental value by
allowing exceptions to patentability based on the concept of
"ordre public" or "morality. 214  Therefore, it is obvious that
ethical issues are incorporated into these two European
instruments in patenting biotechnological inventions.
In comparison with the EPC, the European Directive broadens
the scope of patent protection for biotechnological inventions.1 5
The directive, however, still takes into account compromises
between economic interests and ethical or environmental concerns
more than the EPC does." 6 More specifically, the European
Directive excludes patents on parts of the human body, processes
for cloning human beings or modifying the identity of human
212 Convention on the Grant of European Patents, reprinted in INTERNATIONAL
LEGAL MATERIALS ON INTELLECTUAL PROPERTY 314 (Paul Goldstein ed., 2002 ed. 2002)
[hereinafter the EPC].
213 Directive 98/44/EC of the European Parliament and of the Council of 6 July
1998 on the Legal Protection of Biotechnological Inventions 1998 O.J. (L 213/13)
30.7.98, reprinted in OFFICIAL JOURNAL OF THE EUROPEAN COMMUNITIES, available at
http://europa.eu.int/eur-lex/pri/en/oj/dat/1998/1_213/1_213/9980730en00130021 .pdf
[hereinafter European Directive].
214 According to the EPC provisions, patents shall not be granted in respect to
"inventions the publication or exploitation of which would be contrary to "ordre public"
or morality" and "plant or animal varieties or essentially biotechnological processes for
the production of plants or animals." See the EPC arts. 53 (a), (b), supra note 212. The
European Directive considers "plant and animal varieties" and "essentially biological
processes for the production of plants or animals" unpatentable. The directive
additionally excludes the pantentability of the inventions of which "commercial
exploitation would be contrary to ordre public or morality." See European Directive
arts. 4.1 (a), 4. 1 (b), 6.1, supra note 213.
2M5 Although, in the European Directive, the exception to plant and animal varieties
continues, the eligibility for patenting plants, animals, and their separate elements is
further enhanced, particularly by including the provisions of arts. 4.2 and 4.3. WATAL,
supra note 1, at 154.
216 WATAL, supra note 1, at 154.
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beings, and commercial exploitation of human embryos. 217  The
directive concedes the need for transfer of biotechnology, 28
farmers' privilege to reuse farm-saved seed,219 and breeders' rights
when seeking a compulsory license. 22' This statutory rebuilding,
probably established according to the developments of modem
biotechnology, may be a clue to understanding the relationship
between modem biotechnology and sustainable development.
This trend, conveying relevant interpretational elements to
biotechnological sustainability connotes a substantial change of
the definition of sustainability in the context of patent protection
of modem biotechnology.
B. Evolutionary Interpretation of Sustainability
1. Principle of Evolutionary Interpretation in
International Law
As the WTO Appellate Body correctly pointed out in
interpreting the Preamble to the WTO Agreement and GATT
provisions, 21 evolutionary interpretation of some provisions of
treaties is "well established public international law. 222
Provisions in a treaty should be interpreted in light of the
contemporary concerns of a society.2 3 From this perspective of
evolutionary interpretation supplemented by modem biological
sciences, "renewable" living species or resources should be
included in the category of "exhaustible natural resources" to be
protected as follows:
217 European Directive arts. 5.1, 5.2 and 6.2, supra note 213, at 18.
218 European Directive Preamble, supra note 213, at 13.
219 European Directive art. 11, supra note 213, at 19.
220 Id.
221 "From the perspective embodied in the preamble of the WTO Agreement, we
note that the generic term 'natural resources' in Article XX(g) is not 'static' in its content
or reference but is rather 'by definition, evolutionary."' WTO Report on U.S.
Prohibition on Shrimp, supra note 133, para. 130.
222 Howse, supra note 166, at 520.
223 "The words of Article XX(g) [of the GATT 1994], 'exhaustible natural
resources,' were actually crafted more than 50 years ago. They must be read by a treaty
interpreter in the light of contemporary concerns of the community of nations about the
protection and conservation of the environment." WTO Report on U.S. Prohibition on
Shrimp, supra note 133, para. 129.
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One lesson that modem biological sciences teach us is that
living species, though in principle, capable of reproduction and,
in that sense, "renewable," are in certain circumstances indeed
susceptible of depletion, exhaustion and extinction, frequently
because of human activities. Living resources are just as
"finite" as petroleum, iron ore and other non-living resources.2 4
Similarly, the objective of sustainable development in the
Preamble to the WTO Agreement extends the scope of exhaustible
natural resources to be conserved to include living natural
resources or biological resources.225 Currently, diversity in the
human population, as well as diversity in non-human biological
resources, is considered a contributory element to biodiversity.226
Biodiversity, which on the one hand has been perceived to have an
intrinsic value in international environmental legal systems,227 on
the other hand has demanded protection of the "essentially random
nature of the composition of [human] genes." From the
perspective of genetic diversity in human beings, biodiversity is
probably presented as an ideal to ensure more freedom for
humans.228
Nature and ecology are ceaselessly changing, even
evolutionary. It is now well known that global ecological systems
are not a self-balanced, stable, or "fixed equilibrium," but rather
constantly unstable and mutable. Thus, the earlier definition of
224 Id. para. 128.
225
[R]ecalling the explicit recognition by WTO Members of the objective of
sustainable development in the preamble of the WTO Agreement, we
believe it is too late in the day to suppose that Article XX(g) of the GATT
1994 may be read as referring only to the conservation of exhaustible
mineral or other non-living natural resources.
Id. para. 131.
226 See, e.g., Council of Europe: Draft Additional Protocol to the Convention on
Human Rights and Biomedicine on the Prohibition of Cloning Human Beings, 36 I.L.M.
1415, 1417 (1997) [hereinafter The Council of Europe's Draft Additional Protocol].
227 PHILIPPE SANDS, PRINCIPLES OF INTERNATIONAL ENVIRONMENTAL LAW 1:
FRAMEWORKS, STANDARDS AND IMPLEMENTATION 369 (1995).
228 Council of Europe: Explanatory Report to the Draft Additional Protocol to the
Convention for the Protection of Human Rights and Dignity with Regard to the
Application of Biology and Medicine on the Prohibition of Cloning Human Beings, 36
I.L.M. 1419, para. 3 (1997) [hereinafter The Council of Europe's Explanatory Report to
the Draft Additional Protocol].
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sustainable development based on "equilibrium paradigm," which
required letting the natural environmental system be untouched as
far as possible without human intervention, should be changed to
further integrate the notion of sustainable development built upon
a "non-equilibrium" view in ecology that recognizes appropriate
interaction between humans and nature whereby human culture
and activities can practically contribute to achieve more desirable
environmental structures and maximize ecological conservation. 29
2. Evolutionary Restatement
Historically, the concept of sustainable development has, as we
have already seen, acquired a firm position as a policy objective
for the future of our global community.23 ° Notwithstanding its
established status as a fundamental policy objective in both
national and international environmental legal regimes, sustainable
development has a "potentially self-contradictory" character,
which encompasses contradictory notions of conservation and
economic development.2  In fact, as indicated as follows, the
concept of sustainable development still remains questionable:
"For the present, the concept [of sustainable development] remains
problematic and nebulous, appearing more as a statement of the
issues than as a resolution of the basic problems. As the literature
reveals, the concept is protean in character.,
232
Moreover, the traditional concept of sustainable development
is also on the verge of new challenges in the social, legal, and
political contexts. Presumably, this change of situation has been
229 For more details regarding these "equilibrium" and "non-equilibrium" paradigms
in approaching sustainable development, see generally Guruswamy, supra note 121, at
464-65.
230 Under the WTO Agreement, environmental protection and sustainable
development are recognized as policy objectives as follows:
[T]he preamble attached to the WTO Agreement shows that the signatories to
that Agreement were, in 1994, fully aware of the importance and legitimacy of
environmental protection as a goal of national and international policy. The
preamble of the WTO Agreement - which informs not only the GATT 1994,
but also the other covered agreements - explicitly acknowledges "the objective
of sustainable development."
WTO Report on U.S. Prohibition on Shrimp, supra note 133, at VI (B)(1)(3).
231 Guruswamy, supra note 121, at 464.
232 BROWNLIE, supra note 104, at 287.
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due partly to the inherently double-sided features of sustainable
development, and mainly to the evolutionary developments of
modem biotechnology. Consequently, sustainable development
must be redefined in an evolutionary manner to be compatible
with recent biotechnological revolutions. It is also required that
provisions in a treaty should be interpreted in light of
contemporary context.233  Therefore, in light of recent
developments of genetic engineering, such as cloning
technologies, sustainable development needs to be reconsidered in
novel contexts.234
In addition, according to continuous changes in the concept of
sustainable development, sustainable development has recently
evolved to involve wise use of genetically-engineered human
capital as well as natural resources. This kind of redefinition
means that various policies with the aim to promote sustainable
development should assist innovations to help satisfy human needs
and intergenerational equity.235 As a result, the recent restatement
of sustainable development further emphasizes intervention of
human intellectual activities into the natural world and pays more
attention to the role of science, knowledge, and modification of
nature for sustainable development. This policy approach, of
course, will significantly affect relationships between sustainable
development and biotechnology and its resulting products,
GMOs.236
In conclusion, the revolution of modem biotechnology
instructs us that living resources, including biological or genetic
resources, as well as non-living resources, can be exhaustible, and
that modem biotechnology can either promote or destroy
sustainable development of those biological materials. In
particular, according to the evolutionary characteristics of modem
biotechnology, it will be more reasonable that biological and
genetic resources, including human genetic resources, be treated
within a category of exhaustible natural resources, to be protected
to promote sustainable development. This approach would also be
in conformity with the recently published WTO Ministerial
233 See WTO Report on U.S. Prohibition on Shrimp, supra note 133, at VI (B)(1)(3).
234 See generally Cripps, supra note 1, at 123-26, 133.
235 Guruswamy, supra note 121, at 463-64.
236 Id. at 465-66.
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Declaration on the TRIPs Agreement and Public Health, which
requires flexibility particularly in interpretation of each provision
in the TRIPs Agreement for the purpose of protecting public
health in light of the objective and purpose of the Agreement.237
C. Sustainability in Agricultural Development
1. Implications ofAgro-biotechnology on Sustainable
Agriculture
In practice, sustainable development has been discussed
principally in the agricultural dimension.2 38 Agriculture arguably
has more direct impacts on the environment and sustainable
development than any other industry because cultivation may
release various materials into the earth's land which can seriously
affect environmental ecosystems.239 Materials such as pesticides,
insecticides, fertilizers, or GMOs may be toxic chemicals having
adverse effects on the environment.
From the perspective of agricultural development, narrowly
speaking, sustainability means "resource-conserving, socially
supportive, commercially competitive, and environmentally
sound" farming systems whereby productivity and usefulness to
society can definitely be maintained.24  Broadly speaking;
sustainable development of agriculture has to be understood in the
context of food production that calls for increasing agricultural
productivity, in a sustainable manner, which can on the one hand
significantly meet the additional food demand of future
generations and on the other hand conserve the environment.241
Agricultural unsustainability may accelerate the losses of
arable land essential to produce needed food and existing plant and
animal species whose genetic resources can help make agriculture
more sustainable or produce many other useful products, such as
improved medicines.242 In this respect, it has been argued that
237 See The Declaration on the TRIPs Agreement and Public Health, supra note 193,
paras. 4-5.
238 Cripps, supra note 1, at 121.
239 Barton, supra note 179, at 95.
240 Guruswamy, supra note 121, at 466.
241 Id. at 466-67.
242 Dembach, supra note 103, at 10007.
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biotechnology and its resulting GMOs can bring adverse effects243
as well as various advantages 244 to the sustainability of agricultural
development. Despite the long history of traditional
biotechnological farming practices to produce more desirable
crops or fruits, the peculiarly modem biotechnology of genetic
engineering, such as techniques for transplanting foreign genes
into other species beginning around the second half of the
twentieth century, has fundamentally changed classic cultivation
practices, resulting in our discovery of the utility of ample genetic
resources in the world. This modem biotechnology has been
applied to the agricultural field with a deliberate goal to achieve
fruits or crops resistant to herbicides, insecticides, pests, and
severe weather.
45
2. Promises and Perils of Modern Agro-biotechnology
For the present, it is argued that biotechnology and genetically
modified agricultural plants can be an attractive means to increase
crop yield and produce food with better taste and nutritional
quality, concomitantly reducing production costs and
environmental harm. These promising developments include
stronger and healthier crops containing medicinal properties, as
well as genetically engineered crops, fruits, and vegetables with
enhanced taste, preservation, and nutritional ingredients.246
Despite its alleged potential risks, some insist that biotechnology
is not "inherently dangerous." '247 Additionally, it is also argued
that agricultural biotechnology can create health and
environmental risks similar to those that can be caused by
conventional agriculture.248
Counterarguments have been constantly raised by groups
against application of modem biotechnology to agriculture and the
243 See generally Guruswamy, supra note 121, at 474-77.
244 See generally id. at 469-74.
245 See generally id. at 467-68.
246 See generally id. at 468-74.
247 Van Cleve, supra note 140, at 257.
248 Under this premise, it should be equally noted that risks and costs are also
common in conventional agricultural practices, and therefore, the total social costs must
be measured in comparison benefits and costs between agricultural biotechnology and
conventional agriculture. Id. at 257-59.
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introduction of GMOs into farming systems. They harbor
suspicions about the yet unverified adverse effects of genetic
modifications in agricultural systems.249  In particular,
industrialization of agriculture based on the economic theory of
"minimum cost and maximum production," promoted by
biotechnology and GMOs, prefers monoculture and increases use
of agricultural chemicals with no consideration for genetic safety.
This kind of commercialization of agriculture has been a disaster
to biological diversity."'
In addition, intellectual property protection of agro-
biotechnological inventions may arguably have a significant
meaning for sustainability in agricultural development.
Sometimes application of intellectual property protection to agro-
biotechnologies, such as a genetically modified seed that contains
a "terminator gene" or that is resistant to specific chemical
herbicides or pesticides may be a menace to agricultural
biodiversity, as well as poor farmers. At the end of the 1990s, the
United States granted a patent on a genetic "technology protection
system" that made seeds to work only one growing season. This
technology applied to transgenic and ordinary varieties of seeds,
and even to self-pollinating crops. These genetically modified
plant seeds containing "terminator genes,"which compel farmers
to buy new seeds from the biotech seed companies holding patent
rights every year, require a radical change in the traditional seed
saving practices of farmers for the next season. Moreover, the
spread of cultivation using these seeds increases monoculture,
which may cause adverse effects to agricultural biodiversity.251
Patented crop seeds or plants that are genetically engineered to
resist specific pesticides or herbicides produced by a specific
agrochemical company, which will be destroyed if other products
manufactured by other companies are sprayed on them, have
potential vulnerability caused by a disastrously monocultured seed
stock.252 Of course, these kinds of patent rights will be adverse to
249 See generally Guruswamy, supra note 12 1, at 468-69.
250 Id. at 474.
251 See generally Ketih Aoki, Neocolonialism, Anticommons Property, and
Biopiracy in the (Not-So-Brave) New World Order of International Intellectual Property
Protection, 6 IND. J. GLOBAL LEGAL STUD. 11, 54-55 (1998).
252 Actually, these kinds of herbicide and insect resistant cotton seeds genetically
engineered by Monsanto, which is a multinational agrochemical corporation based in the
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"genomic crop diversity" as well as farmers' interests.253
Criticisms against agricultural biotechnology are mainly based
on unidentified dangers and disadvantages of GMOs to the
environment and human health, such as the long-term effects of
herbicide, insecticide, or pest resistant plants. Critics are warning
that expanding the use of GMOs without securing biosafety will
seriously impair ecological and biological stability. Resistance
enhanced by transgenic techniques, according to their arguments,
can make herbicide resistant crops themselves weeds and increase
the use of environmentally harmful chemicals.254  Similarly,
genetically modified crops containing pesticides such as Bt-corn
were proved to harm Monarch butterfly larvae, "unintended
targets" which are beneficial insects. Further, more powerful
pesticides can produce undesirable new creatures such as new
resistant pests of "killer gene" or "killer weed" that are out of
human control and ultimately lead to serious imbalances in
ecology.255
Accordingly, it should be noted that these kinds of applications
of biotechnology to farming practices may result in a vicious
circle: GMOs give rise to a contaminated ecological system, the
contaminated ecological system to contaminated agricultural
products, contaminated agricultural products to contaminated
food, and contaminated food to contaminated human bodies.
D. Sustainble Use of Human Genetic Resources
1. Human Cloning and Sustainable Development of
Human Beings
a. Application of Technologies
In the case of human cloning, more careful and special
attention needs to be paid to issues of sustainable development.
U.S., turned out to be a catastrophic failure. The cause of that failure was not clearly
ascertained. See id. at 56-57.
253 Id.
254 For example, Round-up Ready soybeans, a herbicide resistant crop, will be a
good example of the need to increase the spray of herbicides in the environment.
Guruswamy, supra note 121, at 476.
255 See generally id. at 475-76.
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Particularly since the advent of the cloned sheep, Dolly, human
cloning has been one of the most controversial issues in social,
ethical, and legal debates. The total ban on human cloning first
proposed by the Council of Europe25 6 does not end the debates.
Rather it ignites severe controversies with regard to two
conflicting policy objectives: protection of social ethics and
morality and protection of technological and scientific
advancement.257
Today's cloning techniques,258 in general, involve two
methods. 9 First, the embryo splitting technique, the classical
method, is the technology that divides an embryo into two pieces,
each of which has identical nuclear genes and a small number of
mitochondrial genes. Second, the nuclear transfer technique, the
revolutionary method, is the technology that transfers the nucleus
of a foreign cell into a reproductive cell so that identical nuclear
genes are produced. 60
Human cloning techniques of somatic cell nuclear transfer
have paralleled more recently developed techniques of embryonic
transfer and embryonic stem cell manipulation. Embryonic
transfer technology is different from that of somatic cell nuclear
transfer in that it transfers the nucleus of an egg rather than a
somatic cell. Specifically, this technology blends nuclei from an
older woman's egg with surrounding cell materials of a younger
woman, fertilizes these mingled egg materials in vitro, and then
implants them in the older woman.26' The technology of
256 See, e.g., The Council of Europe's Draft Additional Protocol, supra note 226, 36
I.L.M. at 1417. For more details regarding the background, general provisions, and
relevant problems of the convention and its additional protocol, see generally Nati
Somekh, The European Total Ban on Human Cloning: An Analysis of the Council of
Europe's Actions in Prohibiting Human Cloning, 17 B.U. INT'L L.J. 397, 400-11 (1999).
257 Somekh, supra note 256, at 397-99.
258 While the specific meaning of the term "cloning" will be defined in respective
provisions of individual legislation, it, commonly speaking, means "the scientific process
of genetically replicating molecules or cells in biological research" from which a whole
organism is created. Id. at 399. When applied to human cloning, it refers to the
reproduction of a completely identical human being. Id.
259 For more details about the types of human cloning, see generally Tracy
Williams, Cloning and the Conservation of Species, 2001 Y.B. COLO. J. INT'L ENVTL. L.
& POL'Y 215, 220-22 (2002).
260 Somekh, supra note 256, at 400.
261 Susan Greenlee, Dolly's Legacy to Human Cloning: International Legal
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embryonic stem cell manipulation mixes undifferentiated
embryonic stem cells from humans with other animals' cells or
eggs to produce a new type of human cell. It is recently reported
that human DNA was fused with a cow's egg. However, there has
been no sufficient evidence of the results of these experiments.262
As we have already observed from the case of Dolly,263 by
using cloning methods, human beings as well as sheep can be
cloned from an adult somatic cell,26 going beyond the natural law
of evolution of life. Moreover, creation of a cloned human by
using embryonic transfer technology is criticized because it may
have defects in both technological and ethical aspects in that the
newborn baby will receive genetic materials from two mothers and
there is a danger that the mothers' genetic diseases will transfer to
the baby.265
b. Unsustainability of Humanity
Human cloning from artificially adapted and selected human
genes can produce more desirable human beings with improved
genetic characters.266 However, this kind of reform in humanity is
likely to court another long-term disaster to mankind caused by
mono-genetics.267 In this respect, the following remark is noted as
an alarm to the people of the world:
Although enhancing human characteristics could benefit people
on an individual level, it might adversely affect the human
Responses and Potential Human Rights Violations, 18 WIS. INT'L L.J. 537, 538-39
(2000).
262 Id. at 540-41.
263 When cloning the sheep, the scientists implanted the nucleus extracted from
somatic cells of an adult sheep into an unfertilized egg from which the nucleus was
removed. After that, this egg was artificially inseminated into a surrogate mother.
Through this genetic manipulation, Dolly, a genetically identical sheep, was born. See
Somekh, supra note 256, at 400.
264 A somatic cell is generally defined as one of the cells of the body that compose
the tissues, organs, or other body cells rather than an egg or sperm cell. Greenlee, supra
note 261, at 538-39.
265 Id. at 539-40.
266 Somekh, supra note 256, at 400.
267 For more detailed debates on human cloning including ethical, moral,
psychological, social, human rights, legal, and religious concerns, see generally id. at
411-20.
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species as a whole. Genetic manipulation could put the human
species at risk by eventually creating a genetically uniform
population. Such genetic uniformity would increase the human
species' susceptibility to annihilation by disease, thereby
weakening its evolutionary fitness and chances of survival as a
species.268
Although it is contradictorily argued that cloning techniques,
particularly so-called "conservation genetics," may significantly
contribute to the conservation of endangered species,269 utilization
of human genetic resources for the purpose of genetic uniformity
is, in the long run, contrary to the sustainable development of
humanity.
Proponents of human cloning particularly focus on its potential
to reduce human suffering. For example, this technology could
provide alternative treatments for infertility, cures for genetically
inheritable diseases, and the means for producing organs and
tissues needed for transplantation. On the contrary, among the
commonly proposed arguments for prohibitions on human
cloning,271 is the idea that the societal harm, in the context of
human genetic diversity, deserves our attention. Human cloning
used for eugenic purposes to achieve preferable genetic traits will
probably result in commodification of humans and long-term
decreases of human genetic diversity, varieties of ideas, and the
genetic fitness of the human species. This kind of diminution of
genetic diversity will, in the long run, endanger the existence of
human society as a whole.2 72
Despite international efforts to regulate creation of genetically
268 Id. at 400.
269 Williams, supra note 259, at 222-23.
270 Andrea Wang, Regulating Human Cloning Within an Environmental Human
Rights Framework, 12 COLO. J. INT'L ENVTL. L. & POL'Y 165, 166-67 (2001).
271 For example, there have been assertions that a cloned child has arguable health
and mental defects originated from the cloning technology itself and knowledge of the
clone of one's self. In addition, in religious and philosophical aspects, the question of
trespass on the divine sectors of creating life and destruction of personality,
individuality, and human dignity resulting from commodification of human beings has
been proposed as a general ethical argument against human cloning. See generally id. at
168-71.
272 Id. at 169-70.
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identical human beings,273 responding to human cloning (including
eugenic uses of it),2 4 there has been no legal or theoretical
consensus for a prohibition on human cloning.275 However, under
the so called "environmental human rights" concept which
emerged as an alternative mechanism for this legal and theoretical
vacuum and which was used to justify international intervention,
human cloning technology for eugenic purposes will often be a
violation of the right to life. 2
6
"Human cloning is not something that once done can be
undone. Any changes in the field are permanent. Once a human
is cloned, it will be hard, if not utterly impossible, to turn back., 277
In the sense of sustainability, therefore, human cloning may be far
from maintenance of the status quo. In addition, in the context of
"environmental human right[s]," human cloning for eugenic ends
will probably create a biological underclass through making
society more genetically uniform, which results in harm to the
genetic diversity of mankind.27 ' This elimination of physical and
behavioral varieties can further deprive human society of cultural
diversity.279 In the field of human cloning, which makes human
gene pools homogenous, there are always possibilities of
rendering the human species more vulnerable to the external
environment and weakening the genetic fitness of the
population.2"0  Thus, it should be equally noted that creation of a
cloned human may, through monoculture of humanity, carry risks
of a decrease of genetic diversity as well as the degradation of
humans into commodities.
273 For more details of both domestic and international responses to human cloning,
see generally Greenlee, supra note 261, at 541-5 1.
274 For the history of eugenic practices including human cloning as a mechanism of
social control worldwide, see generally Wang, supra note 270, at 171-77.
275 Id. at 177-80.
276 Id. at 181-85.
277 Alexandra Hawkins, Protecting Human Dignity and Individuality: The Need for
Uniformity in International Cloning Legislation, 14 TRANSNAT'L LAW 243, 293 (2001).
278 Wang, supra note 270, at 185-86.
279 Id. at 185, 187.
280 Id. at 185, 188.
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2. International Regulations
There have been controversies regarding the technologies of
cloning humans and other animals for the purpose of
conservation. 28 ' Although international regulations on the problem
of human cloning are confusing due to a lack of legislative
uniformity at both the national and international levels, some
countries have regulated or even totally banned human cloning.282
In particular, the European region takes a positive attitude toward
regulation of cloning technologies. In fact, even in the U.S., in
which patenting biotechnology is broadly accepted, claiming
patents on a chimera carrying both animal and human genes has
been rejected on the ground that patents on humans or creatures
that are essentially human are not allowed by Congress, and that
patents on humans are contrary to the U.S. Constitution's
Thirteenth Amendment prohibiting slavery.2 8
3
In the United States, a bill totally banning any form of human
cloning was adopted in the House of Representatives on July 3 1,
2001.284 According to the bill, not only reproductive cloning used
for replicating human beings but also therapeutic cloning,
particularly including nuclear transfer technology and stem cell
research, will be prohibited. 85 However, opponents of this bill
criticize the enactment, contending that the bill neglects the
advantages of somatic stem cell research for medical treatments to
cure various intractable ailments. They also argue that the
creation of cloned humans can be sufficiently prevented under the
current legal system.286 On the contrary, from the perspective of
the environmentalists, cloning technologies for conservative
purposes, whether they are applied to human beings or other
281 See generally Williams, supra note 259, at 215-56.
282 Hawkins, supra note 277, at 244-45.
283 Jasemine Chambers, Note, Patent Eligibility of Biotechnological Inventions in
the United States, Europe, and Japan: How Much Patent Policy Is Public Policy?, 34
GEO. WASH. INT'L L. REV. 223, 231 (2002). It is reported that the 1998 European
Convention for the Protection of Human Rights and Fundamental Freedoms has
counterpart provisions. Cripps, supra note 1, at 125-26.
284 Human Cloning Prohibition Act of 2001, H.R. 2505, 107th Cong. (2001).
285 Williams, supra note 259, at 217.
286 Id. at 217-18. For more details concerning the status and usefulness of the stem
cells, see generally id. at 219.
2003]
N.C. J. INT'L L. & COM. REG.
animals, will not help achieve conservation and protection goals.
Moreover, it cannot allegedly be a conclusive answer for the
survival of all species in the world, but only a "Band-Aid. 287
In Europe, statutory blockage on application of human cloning
technologies has already been tried. The Council of Europe's
Draft Additional Protocol, passed by the Council of Europe on
September 22, 1997 and signed by nineteen states on January 12,
1998, was the first attempt to create a legally binding instrument
that would prohibit human cloning at an international level.288 In
particular, under the Council of Europe's Explanatory Report to
the Draft Additional Protocol, human cloning, including use of
embryonic cells for the purpose of reproducing humans, is
essentially forbidden.289 Additionally, the European Union's
Resolution on Human Cloning, proposed by the European
Parliament, emphasizes an individual right to one's own genetic
diversity and concludes that a ban on human cloning is necessary
to maintain such fundamental rights.29 °
Unlike the former Convention on Human Rights and
Biomedicine,29' which allowed human cloning for "preventive,
diagnostic or therapeutic purposes, 292 the Council of Europe's
Draft Additional Protocol, modifying Article 13 of the Convention
on Human Rights and Biomedicine, was aimed to eradicate human
cloning in all circumstances.293 The Council of Europe's Draft
Additional Protocol prohibits the creation of a genetically identical
human being by splicing the nuclear gene set of another, whether
living or dead.294  Natural genetic combination, allowing every
individual to have various genetic characteristics, can guarantee
287 See id. at 219-20.
288 Heidi Forster & Emily Ramsey, Legal Perspectives on Cloning of Human
Beings, 32 VAL. U. L. REV. 433,454 (1998).
289 See The Council of Europe's Explanatory Report to the Draft Additional
Protocol, supra note 228, 36 I.L.M. at 1419.
290 See Resolution on Human Cloning, 1998 O.J. (C 34) 164.
291 Council of Europe: Convention on Human Rights and Biomedicine, Apr. 4,
1997, 36 I.L.M. 817.
292 See id. art. 13, 36 I.L.M. at 821-22.
293 See The Council of Europe's Explanatory Report to the Draft Additional
Protocol, supra note 228, 36 I.L.M. at 1419.
294 See The Council of Europe's Draft Additional Protocol art. 1, supra note 226, 36
I.L.M. at 1417.
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human freedom more than genetic uniformity which would
seriously threaten the identity of humanity.295 Therefore, under the
Council of Europe's Draft Additional Protocol, requirements of
sustainable use of human genetic resources to secure genetic
diversity of humanity should also apply to human cloning.
However, the European Directive 296 as with the TRIPs
Agreement, 297 does not block the possibility of patent protection
for human DNA and gene sequences.298 This part of the Directive
is thought to be the most significant. Opponents generally
consider such patents to be illegal because they constitute "patents
on life." '299 On this point, accordingly, it is necessary that the
sustainable use of human genetic resources should be taken into
further consideration in intellectual property protection of
biotechnology.
The European Directive expressly adopts "ordre public" or
morality grounds for denying the granting of patents.3  In
addition, the Directive more specifically enumerates human
cloning, modifying the genetic identity of humans or other
animals, and the commercial use of human embryos as non-
patentable inventions." 1 These provisions suggest advances in the
context of sustainable development of humans. Nonetheless, it
should be noted that stem cell procedures can still be patented
unless stem cells are regarded as clones or present embryos within
the meaning of the existing provision.
30 2
To conclude, in light of the irreparable harm to society that
295 See The Council of Europe's Explanatory Report to the Draft Additional
Protocol, supra note 228, 36 I.L.M. at 1419.
296 See European Directive, supra note 213.
297 Under the Article 27.1 of the TRIPs Agreement, "any inventions, whether
products or processes, in all fields of technology" are patentable if the inventions meet
the general patentability requirements. TRIPS Agreement art. 27.1, supra note 137. As
a result, human DNA and gene sequences, in principle, are not excluded from the patent
protection.
298 See European Directive art. 3, supra note 213.
299 However, it is also pointed out that this argument violates basic principles of
patent law. Tade Matthias Spranger, Europe's Biotech Patent Landscape: Conditions
and Recent Development, 3 MINN. INTELL. PROP. REv. 239-41 (2002).
300 European Directive art. 6(1), supra note 213.
301 Id. art. 6(2).
302 Spranger, supra note 299, at 243.
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would probably be caused by human cloning and the international
discrepancy in regulations on it, international agreement is
urgently needed to regulate cloning technologies for the moral and
ethical integrity of the global community 3°3 as well as for the
sustainable development of humanity. Therefore, particularly in
the field of human cloning techniques, in light of multinational
developments, universal efforts to standardize legislation is
essential.3"
IV. Patenting Biotechnology, Biodiversity, and Equity Between
Parties
A. Protection of Biodiversity and Equitable Sharing of
Benefits
As previously discussed, intellectual property protection of
biotechnology, from the perspective of an evolutionary
interpretation, should be understood in the novel contexts of
sustainable development, in which concerns of both diversity and
equity are incorporated. Therefore, review for future rectification
of the legal regime, as well as interpretation of existing legal
provisions concerning intellectual property rights of biotechnology
should promote sustainable development, biodiversity, and
equitable profit sharing. In that sense, the following brief but
suggestive excerpt from Professor Cripps is on point:
In any attempt to renegotiate these provisions of TRIPS, °5
attention must be devoted to the importance of protecting
biodiversity and of sharing the benefits of innovation with the
countries that provide the biological resources. 306
Intellectual property laws of biotechnology, whether they are
national or international, can be a crucial tool to promote
conservation of biological diversity, equitable sharing of benefits,
and ultimately sustainable development. Intellectual property
protection systems that are in place for biotechnological inventions
303 Hawkins, supra note 277, at 245.
304 Greenlee, supra note 261, at 547.
305 For example, TRIPS Agreement arts. 27.2, 27.3, supra note 137. See, e.g.,
Cripps, supra note 1, at 132.
306 Cripps, supra note 1, at 132.
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are also effective legal devices for human rights protection and
environmental conservation, in addition to their primary purposes
- promoting innovations and industrial developments. 30 7 From the
perspective of biodiversity, intellectual property laws may be
applied to all components of the global environmental ecosystem:
species comprising ecosystems and relevant knowledge;
inventories of plants, animals, and microbe species; information
about a species' usefulness; extracts and purified compounds;
methods of preparing such materials; methods of administering
them; seeds, plasmids, and isolated genes; pure-bred or hybrid
crops or animals; synthetic derivatives of compounds and genetic
materials; and products prepared from such compounds. All of
these components, of course, are important in the fields of
medicine, agriculture, and industry.3"8
Issues surrounding modem biotechnology are so various and
broad that they embrace almost all social concerns. Legal aspects
have mostly centered on intellectual property protection of
biotechnological inventions, which may provide an economic
incentive for commercial exploitation of biotechnological
innovations.30 9 However, the question of legal protections of
biotechnologically-modified products and the processes or use of
them310 has concomitantly provoked ethical as well as technical
debates. While the technical issues have included the patentability
of life forms, the ethical issues have focused on whether and to
what extent biotechnological inventions should be protected.311
In principle, when a new biotechnological invention meets the
basic patentability criteria, patent rights may be granted.
However, existing international patent laws allow certain
categories of exceptions based on ethics, public health, and
307 Michael A. Gollin & Sarah A. Laird, Global Policies, Local Actions: The Role of
National Legislation in Sustainable Biodiversity Prospecting, 2 B.U. J. ScI. & TECH. L.
16, para. 39-40 (1996).
308 See generally id.
309 ARUP, supra note 1, at 219.
310 Generally speaking, it has been said that biotechnological inventions fall into
three categories: the processes for the creation or modification of living organisms and
biological material, the results of such processes, and the use of such results.
INTRODUCTION TO INTELLECTUAL PROPERTY: THEORY AND PRACTICE, supra note 3, at
587.
31 UPOV, supra note 203, at 309.
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environmental requirements. In this respect, it is questionable
whether the present patent system as interpreted is appropriate or
sufficient to ensure biodiversity and equitable sharing of benefits
from biotechnological applications.
Indeed, the more biotechnology develops, the more it should
take into account sustainable development concerns based on both
biodiversity and equity. Consequently, provisions stipulated in the
existing international legal instruments to promote sustainable
development (such as patentable subject matter, technology
transfer, protection of indigenous knowledge, preventing
biopiracy, and protection of breeders' and farmers' rights) should
be interpreted and applied with full consideration for biodiversity
and equitable sharing of profits derived from the use of
biotechnology.
In addition to the issues of patentable subject matter, the
matters of promoting technology transfer, protecting indigenous
culture, preventing biopiracy, and protecting breeders' and
farmers' rights may have special meanings to sustainable
development. All of these issues must also be discussed in the
contexts of biodiversity and equity. The next chapter, therefore,
will review these issues within the contexts of existing norms and
future renegotiations, particularly from the perspectives of
biodiversity and equity concerns.
B. Equity Between Generations
1. Intergenerational Equity
A revolutionary consensus that both present and future
generations have equitable rights to share their developmental and
environmental benefits was first attempted in the documents
signed in Rio de Janeiro, introducing a new legal concept:
"intergenerational equity."3"' This principle of intergenerational
equity, which is considered to be an element of sustainable
development, is articulated in many international instruments
aiming to preserve natural resources for the profits of this and
312 Mary Pat Williams Silveira, The Rio Process: Marriage of Environment and
Development, in SUSTAINABLE DEVELOPMENT AND INTERNATIONAL LAW 9, 10 (Winfried
Lang ed., 1994).
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future generations."'
As defined in the Brundtland Report314 and Rio Declaration,315
the principle of intergenerational equity, which is considered
inherent in sustainable development, has intergenerational
implications.316  This intergenerational nature of equity in
sustainable development is succinctly expressed as follows:
[F]uture generations are a silent but important party to debates
about equity. Sustainable development is inherently
intergenerational. The agreements we negotiate are inherently
intergenerational. Yet the interests of future generations have
not been identified and adequately represented in the
negotiations, either in the implementing measures, or in the
compliance mechanisms of international environmental
agreements. The present generations has a bias in favour of
itself. ... Thus, as we consider the future, it will be important
to develop an international consensus on the definition and
outline of the concept of intergenerational equity.317
As far as the future risks flowing from the present use of
biotechnology are concerned, the interests of future generations
should be considered. The existing gene varieties and food stuffs
that are available today must be preserved for future generations.
Sustainable use of present genetic resources is our obligation to
future generations based on the concept of intergenerational
equity.' 18  This kind of equity should be read in the following
modem context, which requires the present generation to ensure
sustainable life for future generations:
The founders of the United Nations set out to promote social
progress and better standards of life in larger freedom - above
all, freedom from want and freedom from fear. In 1945, they
could not have anticipated, however, the urgent need we face
313 Sands, supra note 105, at 58.
314 "Present development must not compromise the ability of future generations to
meet their own needs." WORLD COMMISSION ON ENVIRONMENT AND DEVELOPMENT, OUR
COMMON FUTURE 43 (1987) [hereinafter OUR COMMON FUTURE].
315 "The right to development must be fulfilled so as to equitably meet
developmental and environmental needs of present and future generations." The Rio
Declaration, Principle 3, supra note 118, 31 I.L.M. at 877.
316 Dernbach, supra note 103, at 10013-14.
317 Weiss, supra note 45, at 21-22.
318 McCaffrey, supra note 201, at 101-02.
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today to realize yet a third: the freedom of future generations to
sustain their lives on this planet.319
2. Intragenerational Equity
The negotiation of the CBD revealed that the best reservoirs of
biodiversity exist within developing countries' territories. This
fact made it possible for them to exert control over resources that
are important to the developed world. On the other hand, it should
be equally noted that developing countries are generally apt to
suffer from environmental degradation stemming in part from their
poverty.32 ° Poor people, who live in developing and/or developed
countries, exposed to the worst environmental conditions, are
likely to commit harmful acts to the environment for their
survival.32" ' Therefore, so called "intragenerational" equity,3 22 in
seeking to reduce poverty and environmental degradation, is also
needed to achieve substantially "intergenerational" equity.323
Intragenerational equity, in particular, affirms "the essential
needs of the world's poor, to which overriding priority should be
given" and extends the notion of equity to "equity within each
generation. 3 24  Both concepts are closely connected to trade
policy for poverty alleviation of the world's poor people in the
present generation.325 Therefore, an absolute reinforcement of
intellectual property rights to biotechnology without consideration
of equitable compensations for biologically rich countries for their
genetic resources should be restrained because very limited
number of companies in developed countries can monopolize the
benefits acquired from the resources. Thus, international patent
instruments containing effective measures to prevent biopiracy
from the biologically rich but economically poor countries may be
319 KOFI ANNAN, WE THE PEOPLES: THE ROLE OF THE UNITED NATIONS IN THE 21ST
CENTURY 55 (2000).
320 See generally Weiss, supra note 45, at 21.
321 Dernbach, supra note 103, at 10014.
322 "The principle of intragenerational equity, often overlooked, complements
intergenerational equity as a basic pillar of sustainable thinking." Gaines, supra note
134, at 10331.
323 Dernbach, supra note 103, at 10014.
324 OUR COMMON FUTURE, supra note 314, at 43-44.
325 Gaines, supra note 134, at 10331-32.
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needed for the protection of the global environment.326
C. Patentable Subject Matter
1. Fundamental Policy Tools
The patentable subject matter issues can and must be the most
fundamental policy tool in promoting sustainable biotechnological
development, because the basic scope and direction of
biotechnological developments will depend on how and to what
extent biotechnological inventions are legally protected. Basically
speaking, the scope and extent of protection will be decided
according to requirements for granting patent rights, i.e.
'patentable subject matter.'
During the biotechnological revolution of the last two decades,
the patent system has headed the list of stimuli to industrial
development in the field of biotechnology, including growth of
small businesses, because patent protection of biotechnological
inventions has offered economic incentives for research and
development.327 Therefore, determination of patent eligibility of
biotechnological inventions will be one of the most effective
methods of managing the growth of biotechnological
developments in terms of sustainability.32 8
2. The U.S. and EU
The breadth and degree of protection of biotechnological
inventions varies widely and differs depending on country, region,
and stage of economic development. Grant of a patent in the
United States, which as noted provides the broadest patents on
biotechnological inventions, generally covers human gene therapy,
genetically engineered plants and animals, and their respective
production processes329 based on the premise "anything under the
sun that is made by man."33 Since the landmark case of Diamond
326 Schultz, supra note 131, at 436.
327 Chambers, supra note 283, at 223-25.
328 It is said that the U.S. protects biotechnological inventions more broadly than
any other country in the world. As a result, the U.S. leads the revolutionary development
of the biotechnology industry worldwide. Id. at 241.
329 Id. at 226.
330 Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
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v. Chakrabarty in 1980, allowing the patenting of unicellular
microorganisms,331 the United States has extended patent
protection to complex multicellular living organisms like plants
and animals,332 and even to transgenic mice.333
More recently, human gene therapy,334 as a process, is broadly
patented335 under U.S. patent law.336 When discussing patentable
subject matter, the U.S. authorities hardly address public policy or
morality considerations except in the case of human/non-human
chimera.337 Therefore, the U.S. has not excluded the possibility of
invoking public policy and morality grounds in rejecting
patentability of a human/non-human chimera.338  Patenting
chimeric inventions can be considered to be "injurious to the well
being, good policy, or good morals of society. ' 339
In Europe, in contrast with the United States, certain kinds of
biotechnological inventions are obviously excluded from being
patentable inventions under relevant legal provisions. 340  For
example, "methods for treatment of the human or animal body"
341
including gene therapy, "inventions the publication or exploitation
331 The U.S. Supreme Court approved patentability of genetically engineered oil-
eating bacteria, dictating that the decisive condition in granting a patent is whether the
claimed invention is a result of human manipulation. See id. at 309-10.
332 Chambers, supra note 283, at 228-26.
333 For example, first animal patent on a genetically engineered mouse, the so-called
"Harvard Onco-mouse." See U.S. Patent No. 4,736,866 (issued Apr. 12, 1988).
334 In brief, gene therapy is the insertion of a functional gene into a patient whose
defective gene causes a specific disease. While the entire process may be claimed in the
U.S., the patentable subject matter is a question under ethical debate in Europe, although
the process is used as a method of medical treatment. GRUBB, supra note 1, at 243-44.
335 Chambers, supra note 283, at 231-32.
336 35 U.S.C. § 101 (2000).
337 Chambers, supra note 283, at 226-27.
338 Id. at 230.
339 Tol-O-Matic, Inc. v. Proma Produkt-und Mktg. Gesellschaft, 945 F.2d 1546,
1552-53 (Fed. Cir. 1991).
340 It is reported that, in Europe, from the early 1980s to the beginning of 1998,
many patent applications, totaling up to 15,000, had been filed for biotechnological
inventions. Of these applications, a considerable number of cases are relevant to genetic
engineering, transgenic plants and animals, and human DNA sequences for the purpose
of medical treatment. Gitter, supra note 11, at 5.
341 The EPC art. 52(4), supra note 212.
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of which would be contrary to "ordre public" or "morality," '342 and
"plant or animal varieties or essentially biological processes for
the production of plants or animals" '343 shall not be patented.
Although the concept of "ordre public" still remains uncertain,
EPC's adoption of this morality requirement has been said to have
significantly influenced the development of European patent law
concerning these kinds of biotechnological inventions.344
In interpreting the meaning of "ordre public" or "morality" in
the context of the patent application for a transgenic mouse named
the "Harvard Onco-mouse," which was genetically engineered to
have an oncogene in its genome,345 the Examining Division of the
European Patent Organization (EPO), employing the balancing
test suggested by the Technical Board of the EPO, decided that
"the invention's usefulness to mankind outweighed animal
suffering and risks to the environment. 3 46  Accordingly, we can
find that the EPO has already adopted environmental factors in
applying patents to modem biotechnology, particularly in
patenting higher life forms. Since then, the EPO has defined the
notion of "ordre public" as covering environmental protection as
well as protections of public security and the physical integrity of
individuals. Therefore, under the EPO, inventions which are
likely to involve serious prejudice, the environment would violate
the "ordre public" requirement.347
The European Directive3 48  was prepared to harmonize
European patent policy so as to ensure a competitive advantage in
the field of biotechnology and establish a standardized guide for
patenting modem biotechnological products.349 Compared to the
342 Id. art. 53(a) (emphasis added).
343 This exception, however, does not apply to "microbiological processes or the
products thereof" See id. art. 53(b).
344 David G. Scalise & Daniel Nugent, Patenting Living Matter in the European
Community, 16 FORDHAM INT'L L.J. 990, 1014 (1993).
345 See supra note 333.
346 Chambers, supra note 283, at 235.
347 However, the EPO emphasized the necessity of sufficient substantiation of the
prejudice to the environment. Cynthia M. Ho, Splicing Morality and Patent Law: Issues
Arising From Mixing Mice and Men, 2 WASH. U. J.L. & POL'Y 247, 267 (2000).
348 For more details concerning the history of its enactment, see generally Gitter,
supra note 11, at 9-13.
349 Chambers, supra note 283, at 236-37. "Fearing that the United States would
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former EPC, the directive more specifically enumerates exceptions
to patentability of biotechnological inventions with stricter ethical
aspects. Under the directive, "plant and animal varieties"35 and
"essentially biological processes for the production of plants or
animals"35' are not patentable. The human body, its elements, and
the sequence of a gene cannot constitute patentable inventions,
35 2
but an isolated element from the human body falls within patent
protection.353 In addition, when the commercial exploitation of the
inventions is contrary to "ordre public" or morality, the inventions
are excluded from patent protection.354 This "ordre public" or
morality requirement further applies to the following instances:355
(a) processes for cloning human beings;
(b) processes for modifying the germ line 356 genetic identity of
human beings;
(c) uses of human embryos for industrial or commercial
purposes;
(d) processes for modifying the genetic identity of animals
which are likely to cause them suffering without any substantial
medical benefit to man or animal, and also animals resulting
from such processes.
Obviously the ethical and moral standards in the European
Directive are the most controversial and remain uncertain.
Moreover, vagueness in interpretation of the terms may impede
the directive's objectives: harmonized and appropriate protection
consolidate its lead in the biotechnological field ... [t]he Directive is expected to
guarantee legal uniformity and certainty in providing patent protection for
biotechnological inventions." Spranger, supra note 299, at 235-56. The directive is
designed for effective and harmonized patent protection for biotechnological inventions
and takes into account the ethical dimension in granting patent on the inventions. Gitter,
supra note 11, at 1-2.
350 European Directive art. 4.1 (a), supra note 213.
351 Id. art. 4.1(b).
352 Id. art. 5.1.
353 Id. art. 5.2.
354 Id. art. 6.1.
355 Id. art. 6.2.
356 "Germ line" is defined as "the sequence of cells in the line of direct descent from
zygote to gamete (egg or sperm), as opposed to somatic cells (all other cells in the
body)." Chambers, supra note 283, at 237 n. 114.
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of biotechnological inventions. 357 Although the present European
Directive is, on the one hand, criticized in that "it fails to expel
ethical considerations from patent law," '358  sustainable
development-relevant factors within the biological diversity and
equity contexts should necessarily be taken into consideration in
interpretation and application of the provisions. Further, Article
6.2 of the directive enumerates exclusions from patentability.35 9
3. Operation of the TRIPs Agreement Provisions
Under the TRIPs Agreement, which was established to
harmonize and strengthen international intellectual property
protection,3 6' all kinds of technological inventions that meet
general conditions for patent should be broadly protected3 61 with
the following types of exceptions:
Members may exclude from patentability inventions, the
prevention within their territory of the commercial exploitation
of which is necessary to protect ordre public or morality,
including to protect human, animal or plant life or health or to
avoid serious prejudice to the environment, provided that such
exclusion is not made merely because the exploitation is
prohibited by their law.
362
Members may also exclude from patentability:
(a) diagnostic, therapeutic and surgical methods for the
treatment of humans or animals;
(b) plants and animals other than micro-organisms, and
essentially biological processes for the production of plants or
animals other than non-biological and microbiological
processes. However, Members shall provide for the protection
of plant varieties either by patents or by an effective sui generis
system or by any combination thereof.363
Of these exceptions, from the perspective of sustainable
357 Gitter, supra note 11, at 2-4.
358 Spranger, supra note 299, at 249.
359 Gitter, supra note 11, at 16.
360 Cripps, supra note 1, at 131.
361 TRIPS Agreement art. 27.1, supra note 137.
362 Id. art. 27.2.
363 Id. art. 27.3.
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development, protection of "ordre public or morality"3" including
protection of "human, animal or plant life or health ' 3 65  or
avoidance of "serious prejudice to the environment"3 66 deserves
special attention. These words, according to their ordinary
meanings, which should be the basis of a general rule of treaty
interpretation ,367 can be interpreted to have environment-relevant
implications.368 In particular, this provision, in contrast to the EPC
364 Id. art. 27.2.
365 Id.
366 Id.
367 According to the fundamental principle of treaty interpretation set out in the
Vienna Convention, a treaty and the meaning of a term in that treaty shall be determined
in accordance with the ordinary meaning to be given to the terms in its context and in
light of the object and purpose of the treaty. The Vienna Convention art. 31(1), supra
note 160, 8 I.L.M. at 691-92. This basic rule of treaty interpretation has been expressed
as "customary rules of interpretation of public international" or "a rule of customary or
general international law" applicable to the interpretation of the provisions of GATT
1994 and the other "covered agreements" of the WTO Agreement. See WTO Report of
the Appellate Body, United States-Standards for Reformulated and Conventional
Gasoline, WT/DS2/AB/R at 17 (Apr. 29, 1996), available at ftp://ftp.sice.oas.org
/pub/sice/gasoline.doc; WTO Report on Japan Taxes, supra note 152, at 10; WTO
Report of the Appellate Body, Argentina-Measures Affecting Imports of Footwear,
Textiles, Apparel and Other Items, WT/DS56/AB/R at 17 (Mar. 27, 1998), available at
ftp://ftp.sice.oas.org/pub/sice/wto-wo7/wto24wo7.exe; WTO Report of the Appellate
Body, European Communities-Customs Classification of Certain Computer Equipment,
WT/DS62/AB/R at 6 (Jun. 5, 1998), available at ftp://ftp.sice.oas.org/pub/sice/wto-wo7/
wto28wo7.exe.
368 The GATT 1994 art. XX provides similar provisions read as follows:
Subject to the requirement that such measures are not applied in a manner
which would constitute a means of arbitrary or unjustifiable discrimination
between countries where the same conditions prevail, or a disguised restriction
on international trade, nothing in this Agreement shall be construed to prevent
the adoption or enforcement by any contracting party of measures: ...
(b) necessary to protect human, animal or plant life or health;...
(g) relating to the conservation of exhaustible natural resources if such measures
are made effective in conjunction with restrictions on domestic production or
consumption;...
GATT 1994 art. XX, supra note 172.
Although these provisions do not apparently include the term "environment" anywhere,
these provisions have been regarded as environmental protection-relevant provisions.
See Andreas R. Ziegler, WTO Rules Supporting Environmental Protection, in
INTERNATIONAL ECONOMIC LAW WITH A HUMAN FACE 203, 210-11 (Friedl Weiss et al.
eds., 1998). In practice, in many environment-related trade disputes of the GATT and
WTO, these provisions have been directly invoked by the parties. See, e.g., Report of
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and European Directive, by addition of protecting "human, animal
or plant life or health ' 369 and avoiding "serious prejudice to the
environment '3 70 as examples of "ordre public or morality,' ' 371 can
be deemed to make a meaningful step forward in taking account of
environment-relevant factors. It is unquestionable that biological
diversity mainly concerns both protecting "human, animal or plant
life or health" '372 and avoiding "serious prejudice to the
environment.,
373
Therefore, although the exact meaning and scope of the words
still leave room for more definite interpretations, sustainable
development-relevant factors should be fully reflected in the future
interpretation and application of this provision for patenting
biotechnological inventions. This approach will be more
compatible with the WTO panels and Appellate Body rulings, as
well as with the WTO Agreement, which evidently recognize
sustainable development as an objective of the WTO legal
system3 74  and a principle of evolutionary interpretation in
international law in light of the recent revolution of modem
biotechnology.375
D. Access to Genetic Resources and Technology
1. Access to Genetic Resources
One of the old arguments relating to biotechnology concerns
equity between developed and developing worlds and access to
the GATT Panel on Thailand-Restrictions on Importations of and Internal Taxes on
Cigarettes, DS/1OR - 37S/200, at 8 (Oct. 5, 1990), available at
http://www.sice.oas.org/dispute/gatt/90cigart.asp; WTO Report of the Appellate Body,
United States-Standards for Reformulated and Conventional Gasoline, supra note 367,
at 17; WTO Report of the Appellate Body, EC Measures Concerning Meat and Meat
Products (Hormones), WT/DS26/AB/R at 95 (Aug. 18, 1997), available at
ftp://ftp.sice.oas.org/pub/sice/wtowto7/wto 1 8wo7.exe; WTO Report on U.S.
Prohibition on Shrimp, supra note 133, at 6.
369 TRIPS Agreement art. 27.2, supra note 137.
370 Id.
371 Id.
372 Id.
373 Id.
374 See generally supra Chapter 3, Part I of this thesis.
375 See generally supra Chapter 3, Part 11 of this thesis.
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biotechnology or technology transfer. This issue has been
generally raised by developing countries, most of which are
biologically rich or gene abundant countries, as a "quid pro quo"
for access to their genetic resources.376 In principle, states have
sovereign and exclusive rights over natural resources, at least
within their territories. This principle of "sovereignty of states
over their own natural resources" is favorably upheld by general
rules of international law. Several international instruments
declare this principle as "a valid norm of international law. 37
7
However, the problem of the legal status of indigenous biological
resources, over which the local community has sovereign rights,
remains unsettled. Are these resources international common
heritage or can the concept of biopiracy be applied to these
resources? Can biological samples deposited in gene banks or
under private control be available for public access?
Although the question of whether the meaning of natural
resources in international legal provisions includes biological or
genetic resources is uncertain, they have to be treated as natural
resources under the evolutionary interpretation of biotechnology
and sustainable development in light of developments of modem
biotechnology.378 Furthermore, it is pointed out that, in general,
states' rights over biological or genetic resources are not restrained
under existing international legal rules. 379  The Rio Declaration
also recognizes both the sovereign authority of countries over
natural resources within their territories and their obligations to
prevent transboundary damage to the environment.38°
Access to biological resources associated with the notion of
376 John Ntambirweki, Biotechnology and International Law Within the North-South
Context, 14 TRANSNAT'L LAW 103, 107 (2001).
377 See BROWNLIE, supra note 104, at 542-46; see also Ntambirweki, supra note
376, at 108-09.
378 Contrary to the case of natural resources, there is an argument that genetic
resources have an intrinsic attribute of a common heritage of mankind by which any
exclusive or sovereign right is denied, consequently to which every member in the world
can have access with certain restrictions in international law. However, this claim is
pointed out to conflict with the doctrine of sovereignty over natural resources and the
UPOV under which breeders of new varieties of plants are protected. Ntambirweki,
supra note 376, at 110-13.
379 Id. at 108.
380 The Rio Declaration, Principle 2, supra note 118, at 31 L.L.M. 876.
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sovereign rights over resources, as well as technology transfer, is a
very controversial issue in relation to balancing biotechnology
concerns. 38' Both developed and developing countries' attention
to the significance of access to genetic resources in light of
recently accelerated biotechnological advances and the
enhancement of legal protections in the field of living organisms
resulted in the establishment of the CBD. 382  The CBD tried to
compromise the issues of access to resources and technology
transfer, sovereignty over biological resources, conserving
biodiversity, and state responsibility to conserve and utilize
biological resources in a sustainable manner.383 Under the CBD,
conservation of biological diversity is "a common concern of
humankind" and states have an obligation for conservation and
sustainable utilization of their resources. 84
Despite the fact that the relevant provisions still remain vague,
there lacks a sufficient device assuring practical implementation,
as the CBD declares sovereign rights over genetic resources within
their jurisdiction, and requires fair and equitable sharing of profits
derived from the exploitation of resources.385  In fact,
strengthening developed countries' access to genetic resources and
extending intellectual property rights for biodiversity will likely
limit developing countries' access to those resources. The CBD,
affirming that biodiversity is a sovereign national resource38 6 and
that profits arising out of biodiversity and technology should be
shared with the source country,387 seeks to negotiate conflicting
interests between developing and developed countries.388 Agenda
38, Ntambirweki, supra note 376, at 117.
382 WATAL, supra note 1, at 172.
383 See CBD Preamble, arts. 15, 16, supra note 198.
384 See CBD Preamble, supra note 198.
385 WATAL, supra note 1, at 172. "Reflecting the uncomfortable political deal which
was struck in bringing the CBD to conclusion, the language of the CBD is unfortunately
vague." MACMILLAN, supra note 1, at 119-20.
386 See CBD arts. 3, 5, supra note 198. Article 3 specifically announces sovereign
national right to exploit domestic biological resources. Id. art. 3
387 See id. arts. 1, 16. Article 1 specifically addresses the goals of conservation of
biological diversity, sustainable use of its components, fair and equitable sharing of the
benefits, and reciprocity between access to genetic resources and transfer of relevant
technology. Id. art. 1.
388 Gollin & Laird, supra note 307, para. 7.
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21 also requires equitable allotment of the benefits resulting from
biotechnological development and commercial exploitation of
genetic resources.38 9
In the CBD, Article 15 governs the problem of access to
genetic resources. It mandates that access to genetic resources
should be conducted based on "mutual agreed terms"'3 9 and "prior
informed consent."3 91 And the results and benefits from utilization
of the resources are required to be fairly and equitably shared with
the country of origin of the resources, on mutually agreed terms.
3 92
Although this precondition of mutuality may be a major
contributor to making these provisions ineffective, it can help
prevent unilateral expropriation.393 The CBD, however, deals with
access to genetic resources as a "juxtaposition" against technology
transfer requirements, including biotechnology.3 94
In the case of the TRIPs Agreement, developing countries,
which repeatedly argued that the GATT was not the proper forum
to address intellectual property rights, did not actively participate
in the process of negotiations. As a result, the developing
countries are now seeking to actively take part in future review
procedures of the TRIPs Agreement and the CBD, having
indicated that the TRIPs Agreement does not appropriately deal
with the CBD's dual objectives of access to genetic resources and
equitable sharing of benefits.3 95  Although tension between
conservation and utilization (which are contradictory objectives),
may be aggravated due to the recognition of national sovereignty
over exploitation of genetic resources, facilitation of access to
genetic resources, and preconditions of mutuality and prior
informed consent,"' equitable sharing of benefits should beconsidered at least as a condition for conferring access to genetic
389 See generally Agenda 21, supra note 119.
390 Id. art. 15.4.
391 Id. art. 15.5.
392 CBD art. 15.7, supra note 198. In this context, however, what the terms "fair
and equitable" mean is not certain mainly because mutual agreement is a precondition of
these terms. WATAL, supra note 1, at 172.
393 MACMILLAN, supra note 1, at 120.
394 WATAL, supra note 1, at 172. See CBD art. 16, supra note 198.
395 MACMILLAN, supra note 1, at 129.
396 Id. at 121.
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resources.
2. Technology Transfer
Modem technology, particularly biotechnology, can be a
potential - or a critical - factor to both degrade and restore the
environment, to say nothing of economic development. This
means that easy access to environmentally sound technologies,
including access to special finance plans, is developing into a
critical point of sustainable development policy. In this respect,
technology transfer consistent with sustainable development is
increasingly becoming an important and persuasive policy
objective.397  Consequently, an effective technology transfer
scheme should be an integral part of conventions addressing
sustainable development.
The issue of access to technology or technology transfer in the
international intellectual property protection regime has been
among the most crucial issues in relevant multilateral negotiations
and legal instruments. In particular, the issue of technology
transfer was discussed in relation to the concept of equity in global
society and development of the developing world.398 Fair and
favorable transfer of technology is an essential element in
sustainable use of biological diversity and environmental
protection, and providing and/or facilitating technology transfer is
an obligation of contracting parties for the conservation and
sustainable use of biological diversity and genetic resources.
These requirements of access to and transfer of technology shall,
of course, be consistent with the adequate and effective protection
of intellectual property rights.399
From the perspective of developing countries, agricultural
biotechnology is one of the most significant components for their
economic development as well as the general welfare of their
populations.4 00  In particular, cutting edge agricultural
biotechnology and its products, such as "Golden Rice," are
397 Silveira, supra note 312, at 10-11.
398 Ntambirweki, supra note 376, at 113-14.
399 See, e.g., CBD art. 16, supra note 198.
400 "For developing countries, agricultural improvement is a top priority." Stanley
P. Kowalski & R. David Kryder, Golden Rice: A Case Study in Intellectual Property
Management and International Capacity Building, 13 RISK 47, 63 (2002).
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powerful engines that can help the developing world escape from
fears of poverty and famine."' Moreover, advanced agricultural
biotechnology can play an important role for sustainable
agricultural development. This mechanism can be functioned well
with adequate intellectual property management systems.0 2
However, to the present, most agricultural biotechnologies, which
have been subject to patent protection, have been in the hands of
the private companies of developed countries, which have been
shrinking from transferring their patented technologies to the
developing world °.40  Hence, a more harmonized patent system is
needed not only to implement appropriate intellectual property
protection, but also to facilitate technology transfer from the
industrialized world to the underdeveloped world.40 4
Additionally, in the field of genetic engineering of crops, so
called "second generation transgenic crops" represented by
"Golden Rice," which are known as "value-added innovations,"
have occupied an important position together with so called
former "first generation transgenic crops., 4 5 "Golden Rice," as a
representative model of "value-added innovations," is a
genetically engineered crop containing a higher percentage of
vitamin A. It has a significant value in developing countries, most
of which are suffering from chronic vitamin A deficiency. 6
Therefore, it is necessary that this kind of modem biotechnology
and its products should be effectively, efficiently, and equitably
distributed and transferred from the developed world to the
developing world for the general welfare of the global community.
This strategy, however, can only be successfully implemented
when it is based on mutual trust and an understanding of
intellectual property protection and technology transfer, as well as
ultimately reasonable harmonization of the patent systems of the
401 See id. at 51.
402 Id.
403 Id.
404 See generally id. at 47-50.
405 In comparison to the first generation, transgenic crops genetically engineered to
contain herbicide tolerance, insect resistance, virus resistance, or fungi resistance, the
second generation crops are genetically engineered to contain much more beneficial
nutrition. "Golden Rice" containing a high percentage of vitamin A represents a model
case of the second generation. Id. at 5 1.
406 See generally id. at 51-52.
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world. °7 In this respect, it should be noted that "[t]he genetic
engineering of value-added nutritional quality into Golden Rice is
a turning point both scientifically and in terms of international
technology transfer."40 8
More recently, technology transfer concerns have become an
environmental issue since the United Nations Environment
Programme (UNEP) started to approach the issue based on more
practical purposes, which are conservation of the environment and
equitable sharing of the burden to protect the environment.40 9 As a
corollary concerning environmental protection, the antagonistic
relationship between the North and South in environmental
protection policies mostly stems from the claims that developing
countries cannot implement the same commitments of MEAs as
those of developed countries because of a lack of human,
financial, and technical resources necessary for implementation of
required obligations under those agreements. 410 Addressing these
allegations, many MEAs include provisions dealing with "transfer
of environmentally sound technology," which require special
commitments of developed countries to promote transferring
environmentally sound technology to developing countries.411
During the negotiations of the CBD, the relationship between
access to biodiversity and technology transfer was emphasized as
"two sides of the same coin," which were necessary to be
discussed together.4"2 More specifically, it was insisted that a
balance between the rights and interests of the owners of genetic
resources and technology be recognized.4 3 In the process of the
CBD negotiations, the necessity of transfer technology in utilizing
biodiversity for human benefits was suggested as follows:
[T]he economic dimension including, inter alia, the question of
adequate financial transfers from those who benefit from the
407 See generally id. at 63-67.
408 See id. at 67.
409 Ntambirweki, supra note 376, at 114-16.
410 See id.
41, Gaetan Verhoosel, Beyond the Unsustainable Rhetoric of Sustainable
Development: Transferring Environmentally Sound Technologies, 11 GEO. INT'L ENVTL.
L. REV. 49, 49 (1998).
412 Ntambirveki, supra note 376, at 121.
413 Id.
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exploitation of biological diversity, including through the use of
genetic resources in biotechnology development to the owners
and managers of biological resources and appropriate means to
facilitate the transfer of technical means of utilizing biological
diversity for human benefit ....
After the above-mentioned discussion, Agenda 21 recognized
the need of technology transfer in addition to protecting
intellectual property rights.415  The CBD's Article 16 adopts a
broad and general definition of "technologies that are relevant to
the conservation and sustainable use of biological diversity or
make use of genetic resources" instead of making reference to
specific technology.416  As a result, this provision can be
interpreted to include technology transfer aiming to both develop
biotechnological activities and conserve biological diversity.
However, it should be noted that the former kind of technology
transfer can cause conflict with intellectual property protection.4 17
Under the CBD, issues of technology transfer and access to
genetic resources are linked closely together.418  The CBD
provides contracting parties an obligation to transfer technology,
which is relevant to conservation and sustainable use of biological
diversity without causing significant damage to the
environment.419 In particular, in the event of technology subject to
patents and other intellectual property rights, such access and
transfer should be provided consistently with the effective
protection of intellectual property rights.42°
414 Decision 15/34 of the Governing Council of the UNEP, Preparation of an
International Legal Instrument on the Biological Diversity of the Planet, May 25, 1989,
UNEP/GC/DEC/15/34, available at http://www.unep.org/Documents/Default.Print.asp?
DocumentlD=71 &ArticlelD=785.
415 See Agenda 21 ch. 34, supra note 119.
416 Verhoosel, supra note 411, at 56.
417 Id.
418 "Under Article 16 of the CBD, access to genetic resources is juxtaposed against
requirements on the transfer of technology, including biotechnology." WATAL, supra
note 1, at 172. Both access to and transfer of technology are "essential elements for the
attainment of the objectives of this Convention" that must be fairly and favorably
provided and facilitated on a reciprocal basis. See generally CBD art. 16, supra note
198.
419 See CBD art. 16.1, supra note 198.
420 See id. art. 16.2.
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Developing countries, possessing ample genetic resources,
should be supplied with the technology necessary to use those
resources. 421  Each contracting party shall take measures to
encourage the private sector to facilitate technology transfer for
the profit of both the private sector and governmental institutions
in developing countries.422 The contracting parties, however,
recognizing that patents and other intellectual property rights may
have an influence on the implementation of the CBD, have
obligations to cooperate, subject to national and international laws,
in order to ensure that such rights are supportive and do not run
counter to the objectives of the CBD.423 The fact that Article 16 of
the CBD attempts to reconcile the contradictory interests of both
developing and developed countries predicts the difficulties in the
424future negotiations.
The TRIPs Agreement lightly touches the technology transfer
issue, only recognizing the need for technical cooperation. 425
Similarly, the TRIPs Agreement, by requiring developed member
countries to provide incentives to their enterprises and institutions
to promote and encourage transfer of technology to least-
developed country members so as to enable them to create a sound
and viable technological base,426 takes a somewhat indirect
attitude. However, when considering that the basic objectives and
principles of intellectual property protection are promotions of not
only technological innovation but also international technology
transfer, more attention should be paid to the interests of
technology transfer.427
To conclude, when considering the means to sustainable
growth, technology transfer will be one of the critical issues in
international environmental law in the future.4 28 Thus, the issue of
technology transfer needs to be treated in both the contexts of
421 See id. art. 16.3.
422 See id. art. 16.4.
423 See id. art. 16.5.
424 See WATAL, supra note 1, at 172-73.
425 See TRIPS Agreement art. 67, supra note 137.
426 Id. art. 66.2.
427 ARUP, supra note 1, at 244.
428 Colin M. Alberts, Technology Transfer and Its Role in International
Environmental Law: A Structural Dilemma, 6 HARV. J.L. & TECH. 63, 64 (1992).
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reducing poverty in the developing world and sustainable
development of a global environment system. However, although
the term "technology transfer" is not a new item on the
international agenda, but instead is one of the old businesses in
international relations, the vagueness of its definition has led to
ineffective commitments relating to technology transfer.
12 9
Therefore, a reasonable compromise between access to genetic
resources and technology transfer should be sought on the basis of
appropriate protection of intellectual property rights of
biotechnology. At the same time, intellectual property rights
should not be barriers to the transfer of environmentally sound
technology required to promote sustainable development. A
patent system for biotechnology should be a further stimulus to
research, development, innovation, diffusion, and transfer of new
technologies. Future plans for intellectual property protection
must be compatible with more enhanced scheme for transfer of
environmentally sound technologies.
E. Indigenous Knowledge and Biopiracy
1. Protection of Indigenous Culture
From the perspective of biodiversity with relation to
sustainable development, it is insisted that indigenous peoples, in
general, have the rights "to control their land and the natural
resources on those lands" and "to control and receive benefits
from the dissemination and use of their knowledge.""43 Therefore,
it should not be disregarded that indigenous peoples play a
significant role in promoting biodiversity, and their traditional
knowledge must be protected as a result of their intellectually
creative activities.43 Although it is pointed out that intellectual
property protection of indigenous knowledge and biological
resources may have potential dangers, such as keeping technology
out of the public domain, increasing costs of technologies, creating
monopolies, and making it difficult to grant patents to inventions
involving living organisms, medical therapeutics, traditional
knowledge, etc., it is also true that intellectual property rights for
429 Verhoosel, supra note 411, at 49, 51.
430 Gollin & Laird, supra note 307, para. 33.
431 Id.
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them can be an effective engine to propel utilization of biological
materials. Consequently, national as well as international
intellectual property laws should be adequate legal tools to
promote biodiversity.4
3 2
Conventional practices and traditional knowledge of farming
and conservation activities, which succeeded for generations in a
sustainable manner, and preserving and expanding the gene pool,
may be imperative elements for "long-term food security" and,
ultimately, "long-term survival." '433 Transcended plant and animal
varieties and traditional information of them within a community
should be respected as a treasure-house: a natural reservoir of
genetic resources.434 As a matter of fact, without appropriate
protection of this traditional knowledge and localized genetic
materials, neither legitimate protection of intellectual property for
biotechnology nor balancing interests can be expected.435
Nevertheless, to the present, due attention has not yet been paid to
the role and protection of these rural and traditional cultures. 436
Studying, experimenting, commercially exploiting, and
elsewhere patenting a biological sample obtained from gene-rich
developing countries can remove the new invention from the
public domain. As a result, this application precludes indigenous
farmers from using existing species or practicing traditional
agricultural methods. Hence, patents on this kind of material or
information should be properly and restrictively issued to cover
only the new aspects of an invention in order to prevent monopoly
of the creation, and to leave the prior materials in the public
domain as much as possible.437 The patent system applied to such
cases, therefore, should take into sufficient account special
compensation for indigenous peoples' contribution to sustaining
genetic resources which may have spiritual, traditional, and
customary meanings to them.438
At the international level, there have already been efforts to
432 See id. paras. 41-44.
433 Cottier, supra note 18, at 558.
434 ARUP, supra note 1, at 223.
435 Cottier, supra note 18, at 563.
436 Id. at 560.
437 Gollin & Laird, supra note 307, para. 56.
438 ARUP, supra note 1, at 223.
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protect traditional knowledge and intellectual creations of
indigenous peoples.439 These include recognition of property
rights for flora and fauna and a moratorium or prohibition on
commercial utilization of biogenetic resources without indigenous
peoples' consent."0 In addition, there are cases in national courts
concerning protection of traditional resources, which are assessed
to have a significant implication, particularly in protecting the
residences of indigenous peoples.44' Traditional notions of legal
protection in both the fields of resource allocation and traditional
knowledge, however, require review.442
Of the existing legal regimes that can be used to protect
indigenous peoples' interests, both environmental and intellectual
property laws are the most relevant. However, the existing
intellectual property legal system is deemed to be inadequate for
protecting traditional (or "existing") knowledge since patent rights
are generally granted to "novel" creations.443 Thus, protection of
indigenous peoples' traditional knowledge and their creativity
must be sufficiently taken into consideration in future negotiations
for reforming international intellectual property protection of
biotechnology.
To date, some international declarations have dealt with issues
of indigenous property rights, yet most of them have allegedly
acquired a position of "soft law." '444  The Rio Declaration
obviously recognized that indigenous peoples and communities,
and their traditional knowledge and practices have an essential
role in both contexts of environmental management and
development. 45  Agenda 21 tried to protect indigenous and
traditional knowledge,446 arguably by some kind of intellectual
property rights.447 Under Agenda 21, member states are directed
to adopt national policies and laws with aims to protect indigenous
439 Gollin & Laird, supra note 307, para. 56.
440 Id. para. 30.
441 Cottier, supra note 18, at 568.
442 Id. at 560.
443 Gollin & Laird, supra note 307, paras. 34-36.
444 ARUP, supra note 1, at 245.
445 See The Rio Declaration, Principle 22, supra note 118, at 880.
446 See Agenda 21 ch. 26, supra note 119.
447 Gollin & Laird, supra note 307, para. 16.
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intellectual and cultural property.448 More specifically, Agenda
21, emphasizing the relationship between indigenous peoples and
their lands,44 9 asks for establishment of national processes to
strengthen indigenous and traditional knowledge to promote and
ensure environmentally sound and sustainable development.450
The CBD, which is probably the most important international
legal instrument concerning indigenous knowledge issues, shows
the difficulties in managing this problem. 5' The CBD, on the one
hand recognizes the intimate relations between indigenous
communities and their biological resources, and the equitable
sharing of benefits arising from the use of traditional knowledge
relevant to the conservation and sustainable use of components of
biodiversity.4 52 On the other hand, it directs each contracting party
to respect, preserve, and maintain indigenous knowledge relevant
to the conservation and sustainable use of biological diversity.453
Additionally, like the case of traditional knowledge, rights
over traditional resources and innovations in the fields of
agriculture and pharmaceuticals relating to genetic engineering
probably have a significant meaning in the international trading
system. Consequently, protection of them will also be closely
related to the WTO legal system.454 Therefore, present trade rules,
as well as intellectual property rules, should be rebuilt to promote
sustainable use of diverse biological resources by allowing the
indigenous people and national governments of biologically rich
countries to be granted a certain amount of intellectual property
protection and economic benefits for their optimal use of the
genetic resources, traditional knowledge, and indigenous culture to
conserve "biodiverse ecosystems. 455  The future TRIPs
Agreement negotiations should therefore take into full
consideration the issue of protection of indigenous knowledge in
the field of genetic engineering, as well as genetic resources in the
448 See Agenda 21 ch. 26, supra note 119.
449 MACMILLAN, supra note 1, at 127.
450 See Agenda 21 ch. 26.3(a), supra note 119.
451 ARUP, supra note 1, at 245.
452 See CBD Preamble, supra note 198.
453 See id. art. 8(j).
454 Cottier, supra note 18, at 581-82.
455 Schultz, supra note 131, at 436-37.
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context of "a Millennium Round., 456
2. Prevention of Biopiracy
Very frequently, imprudent biopiracy by the developed world
purely for economic benefits may result in deterioration of
biodiversity and infringement of indigenous peoples' rights in
developing and the least developed countries. For example, the
U.S. and Japanese companies' patents on a number of useful
products extracted from the "neem tree," an Indian plant which
has versatile medical and agricultural usefulness,457 led to
monopolized massive consumption of neem seed by a limited
number of corporations and wealthy people in developed
countries.458  This exclusive exploitation by a small number of
companies fanned price increases of the seed that local users
cannot afford, and ultimately made it possible for companies
holding patents to control access to and use of the neem tree.4 59
In fact, it is rather ironic that "property-rich" countries' piracy
of "gene-rich" countries' traditional properties is likely to occur
more frequently.4 60 Another interesting example of this so called
"biocolonialism" may be the case of "African Soapberry" which
456 See generally Cottier, supra note 18, at 556, 581-84.
457 Traditionally, its bark, flowers, seeds, and fruit have been used as various
medicines, branches as an antiseptic toothbrush, oil as an ingredient in toothpaste and
soap, and residue as a potent insecticide against locusts, nematodes, mosquito larvae,
boll weevils, and beetles. Aoki, supra note 251, at 5 1.
458 In October 1993, the Indian farmers who had used neem seed in their traditional
farming communities severely protested against and objected to patenting neem seed.
See id. at 53.
459 Id. at 51-52.
460 "[l]nvaluable biological and cultural resources flowing out of the countries of the
South as 'raw material' into the developed nations of the North where there are
magically transformed in the laboratories of pharmaceutical and agricultural corporations
into protected intellectual properties whose value is underwritten by provisions of
multilateral agreements such as TRIPs." Id. at 49. This phenomenon has been
straightforwardly demonstrated in the following testimony:
The United States has accused the Third World of piracy. The estimates for
royalties lost are $202 million per year for agricultural chemicals and $2.5
billion annually for pharmaceuticals .... However if the contributions of Third
World peasants and tribespeople are taken into account, the roles are
dramatically reversed: the United States would owe Third World countries $302
million in agriculture royalties and $5.1 billion for pharmaceuticals.
VANDANA SHIVA, BIOPIRACY: THE PLUNDER OF NATURE AND KNOWLEDGE 56 (1997).
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has for generations been used as insecticide and fish intoxicant.
An Ethiopian researcher found that the African Soapberry had
effective toxicity to kill water-snails carrying the disease bilharzia.
However, the original discoverer and reporter in the resource
country was never rewarded for his discovery after an English
institute patented an extraction process to produce commercial
material to kill zebra mussels that clog North American
waterways.461
If just the discoverers of traditionally recognized species are
compensated for their discoveries, indigenous peoples' rights can
be easily infringed and the profits from discovered species will be
mainly devoted to outsiders' pockets. Consequently, rewarding
discoverers can contradict the idea of biodiversity conservation
and equitable sharing of benefits.462  Recently, developing
countries faced with this kind of biopiracy by private companies
have attempted to pass legislation to protect their indigenous
biological resources.4
63
Under the existing international legal "regime," this practice of
biopiracy is inevitably adverse to traditional farming systems and
environmental conservation.464 The current legal system cannot
defend against daily-occurring biopiracy or the unfair activities of
biotechnology companies pirating genetic resources, patenting
them, and monopolizing the benefits which originally belong to
indigenous communities. For example, according to the TRIPs
Agreement, Indian original basmati rice on which U.S. companies
hold patent rights cannot be exported from India or Pakistan.
Consequently, Indian local farmers' market interests are denied. 65
Biopiracy can also be applied to human beings in relation to
modern biotechnological developments. After granting patents to
genetically engineered oil-eating bacteria4 66 and to genetically
461 Aoki, supra note 251, at 52.
462 Gollin & Laird, supra note 307, para. 65. In many cases, outsiders instead of
indigenous people are likely to receive profits resulting from exploitation of genetic
resources. See James 0. Odek, Bio-Piracy: Creating Proprietary Rights in Plant
Genetic Resources, 2 J. INTELL. PROP. L. 141, 148 (1994).
463 See generally Aoki, supra note 25 1, at 50-5 1.
464 Alberto Szekely, Modified Organisms and International Law: An Ethical
Perspective, 14 TRANSNAT'L LAW. 129 (2001).
465 Id. at 134.
466 See supra note 331 and accompanying text.
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modified mice,467 there is a question of whether genetically
engineered humans or human parts can be patented.4 68 The U.S.
attempt to patent a cultivated cell line from the blood of a woman
of the Guayami tribe in Panama caused global repercussions. In
the early 1990s, U.S. researchers cultivated a cell line from blood
samples of a woman infected with hairy-cell leukemia which was
widespread among the tribe, and applied for a patent on it. As a
result, the European Parliament began to ban patenting life-forms,
and all strata of society, particularly the press, religious world, and
indigenous communities, sharply opposed the grant of a patent.469
Additionally, in the contexts of public health and sustainable
development of humans, the developed world's interests in the
exclusive exploitation of traditional medicinal resources can
represent a type of biopiracy. Also, modernized use of indigenous
medicines by pharmaceutical companies in developed countries
can be a critical obstacle to easy access to traditional medicine
because of a rise in costs due to intellectual property protection.47 °
As illustrated in the above cases, allowing this kind of
biopiracy will oppose international cooperations for sustainable
development. Application of intellectual property rights to
traditional cultures does not fit because in those communities
traditional knowledge is shared among all of their members.47'
Therefore, genetic resources and grassroots innovations in the
developing world should be legitimately respected and protected.
Indigenous people have to be compensated and rewarded for their
supplies of biological resources. An intellectual property
protection scheme incorporating just remuneration for indigenous
knowledge will thus help promote sustainable development.472
F. Breeders 'and Farmers' Rights
Plant breeders' rights over new sexually reproduced plant
varieties have a significant role in promoting biodiversity because
467 See supra note 333.
468 Aoki, supra note 251, at 52-53.
469 Id.
470 David P. Fidler, Neither Science Nor Shamans: Globalization of Markets and
Health in the Developing World, 7 IND. J. GLOBAL LEGAL STUD. 191, 221 (2001).
471 Cripps, supra note 1, at 129.
472 Id.
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a wild variety locally bred for several generations can be protected
by these rights.473 This kind of variety is primarily subject to
UPOV, and exclusive rights may be granted to a breeder who
breeds a novel, distinct, uniform, and stable plant variety. 4
UPOV, which was recently revised in 1991, concerns protection of
plant breeders' rights. It tends to reinforce the protection of
breeders' rights following the current international trend of
strengthening intellectual property protection.475 Therefore, the
recently revised UPOV strengthens the breeder's rights over
access to resources.476
Under UPOV, "breeder" means "the person who bred, or
discovered and developed, a variety. 4 77  When the variety is
"new, distinct, uniform and stable," breeders can claim4 78
breeders' rights. Similarly, the TRIPs Agreement requires
member countries to provide protection for plant varieties by
patents. However, more adequate principles of international
norms are needed to effectively regulate these issues.479
UPOV has made an effort to balance owners' rights and the
need to provide access to the varieties. In addition, the UPOV
system has offered a positive incentive to the breeders who have
been left out by patent protection, which mainly focuses on high
technologies. 48' A plant variety must meet the requirements of
being distinct, homogenous, and stable in order to be protected.
These requirements mean that a new plant variety has to be
sustainable for generations as well as different from existing plant
species.48" ' Plant breeders' rights, therefore, may, in part,
contribute to the promotion of biological diversity.
Historically, the notion of farmers' rights has stemmed from
attempts to recognize their rights arising from their contributions
473 Gollin & Laird, supra note 307, para. 57.
474 See UPOV art. 5(1), supra note 203.
475 Ntambirweki, supra note 376, at 120.
476 ARUP, supra note 1, at 236.
477 UPOV art. I(iv), supra note 203.
478 Id. art. 5(1).
479 Protection by an effective sui generis system is also allowed. See TRIPS
Agreement art. 27.3(b), supra note 137.
480 ARUP, supra note 1, at 234-35.
481 Id. at 235.
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to conservation, improvement, and utilization of plant genetic
resources. 482 It particularly focuses on promoting more equitable
relations between the parties483 in addition to the farmers' rights of
using plant genetic resources and gaining profits from the use.484
Farmers who have played an important role in developing genetic
resources over generations should be given proper reward for their
contribution. In fact, profits as well as responsibility concerning
the conservation and exploitation of genetic materials, in the sense
of sustainable development, should be equitably shared in global
society. Recognition of farmers' rights can help achieve this
policy goal through the sustainable use and improvement of
genetic resources.
485
As developing countries generally argue, their farmers, who
have traditionally discovered, cultivated, and bred plant varieties
for generations based on genetic materials in their territories, have
priority over such genetic resources. Further, there is no just
rationale for allowing developed countries' free access to the
genetic materials without any payment to the farmers.486 The CBD
does not specifically articulate farmers' rights or considerations
for collaboratively innovated plant varieties in a local community.
Instead, member countries can autonomously establish their own
legal framework regarding the problem.487 However, as of now,
no agreement has existed to enforce compensation for farmers and
finance it in spite of the general acceptance of the concept.488
V. Conclusion
Sustainable development is not a simple goal, but is and
should be a real normative objective in the modem context of the
482 See, e.g., Annex II, Res. 3/91, 25th Sess. of the FAO Conference, Rome, 11-29,
Nov. 1989. "The concept . . . was formulated . . . as a basis for recognizing and
rewarding the contribution of farmers to the conservation and management of plant
genetic resources." See also MACMILLAN, supra note 1, at 126.
483 MACMILLAN, supra note 1, at 126.
484 Cottier, supra note 18, at 564-65.
485 For this function of farmers' rights, see generally Ntambirweki, supra note 376,
at 112.
486 Ntambirweki, supra note 376, at 111-12.
487 WATAL, supra note 1, at 173.
488 MACMILLAN, supra note 1, at 127.
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new biotechnological millennium. From the perspective of the
modem biotechnological revolution, sustainable development
needs to be redefined to include all relevant factors: sustainability
in agriculture and human genetic resources,489 promotion of
biological diversity and equity between parties, and balancing
between intellectual property protection of biotechnological
inventions and sustainable development. This restatement should
be based on an evolutionary interpretation in light of modem
biotechnological development. In this respect, a more evolutionary
interpretation of and approach to biotechnology and sustainable
development, which incorporates all factors relevant to sustainable
development in light of recent biotechnological revolution, is
needed.
The evolutionary interpretation supplemented by modem
biological science urges us to include renewable living species or
resources, such as genetic resources in the human body, as well as
biological resources in the ecosystem, into exhaustible natural
resources to be protected under existing international laws.
Therefore, intellectual property protection of biotechnology should
further take into account the conservation of biodiversity of all
kinds of natural resources, including human genetic resources.
Moreover, in light of recent innovations of biotechnology, steady
and long-term endeavours in order to interpret and apply the
existing relevant norms to encompass the concept of sustainable
development, which is based on both sustainable development of
agriculture and sustainable use of human genetic resources, should
be made.
In the case of genetic modification of human beings, more
careful and special attention needs to be paid. In particular, it
should be noted that human cloning for the purpose of artificial
selection or adaptation of human genes may bring an unexpected
489
The concept of sustainable development has always been ill defined, some
would say empty, but there has been consensus about its context. It has been
assumed that the topic is confined to agriculture .... [T]he rapid development
of the technologies of genetic modification and cloning and the patenting of
genetically modified animals, human gene sequences, and stem cells impel us to
consider the concept of sustainable development in novel contexts that include
the cloning of creatures and embryonic stem cells for use as spare parts.
Cripps, supra note 1, at 133.
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long-term disaster to human society caused by mono-genetics.
Consequently, genetic manipulation of human beings, which could
result in reckless genetic uniformity of the human species, must be
strictly regulated and controlled in both the domestic and
transnational legal systems. In light of irreparable harm to the
sustainability of human society, an international legal consensus to
regulate human cloning technologies should be quickly established
because elimination of cultural as well as physical diversity in
human society resulting from the monoculture of humanity will be
contrary to the sustainable development of human beings.
Intellectual property protection of biotechnology - more
specifically speaking, patenting biotechnology - should be
understood in the novel contexts of sustainable development in
which protection of biodiversity and equitable sharing of benefits
are equally incorporated. Thus, whether it would be national or
international law, intellectual property protection laws of
biotechnology must be more favorable to the harmonization of an
integral triad of policies: conservation of biological diversity,
assurance of equitable sharing of profits, and sustainable
development. These legal regimes should also cover not only all
components of the global environmental ecosystem, but also social
concerns, including ethics, morality, public health, etc. However,
the political function of intellectual property protection providing
economic or commercial incentives for legitimate exploitation of
biotechnological innovations should not be ignored. This premise
may help draw a line of equilibrium between development and
conservation.
Indeed, when contemplating desirable uses of global biological
resources in a sustainable manner, a generally accepted definition
of sustainable development in global society is needed. In this
respect, in addition to biodiversity, equity should be given priority
in sustainable development concerns because this approach can
secure greater approval from more members of the global
community. Therefore, equity issues surrounding intellectual
property protection of biotechnology must seek to balance
interests between present and future generations, providers and
users of the biotechnological inventions in question, and
developing and developed countries. This is the very reason why
patenting biotechnology should take into consideration the
promotion of biodiversity, patentable subject matter, access to
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genetic resources, technology transfer, and protection of
indigenous knowledge. To achieve all of these policy objectives,
the patent system of biotechnology should also be compatible with
the goals of conservation, sustainable use, and equitable sharing of
the benefits of biodiversity.
To promote biological diversity, first of all, the patentable
subject matter of biotechnological inventions, which can decide
the basic scope and direction of biotechnological applications,
should be interpreted and applied in a sustainable manner. On this
point, in particular, the "ordre public" or morality requirement,
including protection of "human, animal or plant life or health" and
prevention of "prejudice to the environment" contained in existing
national or international norms, should be fully reflected in
granting patents to biotechnological inventions. More specifically,
patentable subject matter provisions must be interpreted to include
environmentally sound technologies but exclude environmentally
unfriendly technologies from patentable technologies. Hence, the
patent system, through patentable subject matter provisions,
should perform its substantial function to distinguish
environmentally unfriendly technologies from environmentally
friendly ones.
In addition to the protection of biodiversity, sustainable
development in modem contexts requires balancing interests
between the parties. Therefore, benefits from the global biological
resources and exploitation of them should be equitably shared
between providers and users of the resources. In particular, legal
programs for more effective access to genetic resources and
technology transfer should be an integral part of agreements
regulating intellectual property protection of biotechnology.
These schemes must also promote sustainable uses of biological
diversity and genetic materials. This political strategy requires a
harmonized patent system in the world, based on mutual trust and
understanding regarding both appropriate intellectual property
protection and technology transfer. At the same time, intellectual
property rights should not be barriers to the technology transfer,
which is required to promote the sustainable development as well
as the reasonable access to biodiversity necessary for
biotechnological advances.
More practically, in future discussions for reforming the
international patent regime of biotechnology, sufficient incentives
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to conserve indigenous biological resources and local culture in
the source countries, which can contribute to promote sustainable
development in global society, should be taken into account.
Existing intellectual property legal systems, on both national and
transnational levels, allowing biopiracy by the developed world to
take the underdeveloped world's traditional and biological
resources and transform them into patented intellectual properties
without just compensation for resource countries under the name
of intellectual property rights, must be re-examined. In this
regard, future negotiations for multilateral trading legal systems
such as the TRIPs Agreement, as well as MEAs, have to seek
consistency and harmony among obligations of technology
transfer, rights of access to genetic resources, protection of
indigenous knowledge, and protection of intellectual property
rights to biotechnological inventions. In particular, this policy
approach should aim to reduce the economic developmental gap
between the North and the South, which is still a negative element
for sustainable development in the global society.49 °
As for uses of human genetic resources and human cloning
technologies, the question of whether any trials to clone human
beings violate human rights, degrade human dignity, impair
human identity, or demote the sustainability of humanity should be
repeatedly scrutinized by the global community. Particularly,
human cloning for the purpose of reproducing human beings
should be put under the consistent surveillance of international
organizations, whether intergovernmental or nongovernmental.4 9'
In conclusion, future negotiations for intellectual property
protection of biotechnology should be founded on a new policy
approach for sustainable development integrating all kinds of
concerns surrounding modem biotechnological innovations such
as the environment, biodiversity, trade, agriculture, medicine,
equity, and humanity. This integral approach will be applied to a
triad of policies - trade, environment, and development - in future
international trade negotiations. 492 Both national and international
regulations on biotechnology such as intellectual property laws,
accompanying this political integration, should be an effective
490 Gaines, supra note 134, at 10347.
49t Greenlee, supra note 261, at 554.
492 Gaines, supra note 134, at 10346.
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policy tool to maximize social benefits, yet minimize social
expenses, taking into account both profits and costs derived from
intellectual property protection of biotechnology in the context of
sustainable development.
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